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ABSTRACT 
IMMOBILIZED COBALT AFFINITY PURIFICATION FOR HSV-1 BASED GENE 
THERAPY VECTORS 
Canping Jiang, PhD 
University of Pittsburgh, 2006 
Herpes simplex virus type 1 (HSV-1) is a promising vector for gene therapy applications. 
To be used as therapeutic agents, HSV-1 vectors must meet the stringent criteria of high titer 
and purity. Thus, development of scalable, efficient HSV-1 vector purification strategies is 
essential to advance HSV-1 vectors into clinic. 
In this dissertation, a novel, efficient HSV-1 vector purification method, based on 
immobilized metal affinity chromatography (IMAC), was developed.  
I first evaluated the feasibility of using various transition metal ions (Cu2+, Zn2+, Ni2+, 
and Co2+) for the purification of HSV-1 vectors. Results show that none of the metals 
investigated provided a means of separating the virus from impurities. However, of interest is 
the finding that neither the virus nor the impurities bound to immobilized Co2+, suggesting 
that this metal could be useful for HSV-1 vector purification if the vector could be endowed 
with the affinity toward cobalt.  
Accordingly, I constructed an HSV-1 recombinant bearing a cobalt affinity tag (HAT) in 
the heparan sulfate binding domain of the virion envelope glycoprotein B (gB). It was found 
that the productivity and infectivity of the tagged HSV-1 mutant (KgBHAT) was not 
adversely affected by the mutation; while the binding and elution of KgBHAT on cobalt 
charged iminodiacetate (IDA-Co2+) columns confirmed that efficient purification was 
possible. By reducing cobalt ion leakage and optimizing the loading conditions, flow rate,  
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and chromatographic substrate, efficient purification of KgBHAT from crude supernatant was 
achieved with over 70% virus infectivity recovery and over 95% reduction in protein and 
DNA impurities. 
Finally, I found that purification of KgBHAT on IDA-Co2+ columns using crude 
supernatant as starting material resulted in significant loss in virus infectivity. Electron 
spinning resonance revealed that the virus inactivation was caused by hydroxyl free radicals 
generated from the interaction between cobalt ions and components in crude virus 
supernatant. Appropriate amounts of free radical scavenger, a free radical scavenger, or 
imidazole in the loading material was able to protect HSV-1 from inactivation, and led to 
high virus infectivity recovery from IMAC purification. This finding is the first report of free 
radical mediated biological inactivation in an actual IMAC purification. 
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1.0 BACKGROUND 
1.1 GENE THERAPY AND GENE THERAPY VECTORS 
1.1.1 Gene Therapy 
The completion of the human genome project and progress in life science and medicine 
have resulted in an abundance of information about the molecular and cellular basis of human 
diseases, which enables the exploration of new therapeutic approaches based on engineered 
genes and cells.  
Gene therapy is a new therapeutic modality that aims at correcting genetic defects or 
expressing proteins that are therapeutically useful. In most applications, gene therapy can be 
defined as the transfer of genetic materials (DNA or RNA) to cells of a patient which results 
in a therapeutic effect1-3. Gene therapy has several advantages over existing therapeutic 
approaches based on small molecules and proteins. These include: (i) correction of the 
genetic cause of a disease, (ii) in situ production of drugs in affected cells or tissues, and (iii) 
potentially long-term therapeutic effect after single application. As a result, gene therapy 
provides the potential for the treatment of many acquired and inherited human diseases where 
conventional clinical procedures are less effective. These diseases include monogenic 
disorders such as cystic fibrosis4, 5, but also more complex disorders, such as cardiovascular 
diseases6, 7, diseases of nervous system8, 9, autoimmune diseases10, and cancers11, 12. 
Although the theoretical advantages of gene therapy are obvious, so far gene therapy has 
not met its promised goals: the existing clinical experience indicates insufficient therapeutic 
efficacy, while concerns were raised regarding the safety of gene therapy. 
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One of the most formidable obstacles of gene therapy exists in gene delivery. In order to 
achieve the desired therapeutic effect, the therapeutic gene has to be delivered into a specific 
cell population in a target tissue; and the gene has to be expressed in a safe and regulated 
manner for an appropriate period of time. Thus, success of gene therapy requires not only the 
identification of suitable therapeutic genes, but also the development of gene delivery 
systems of sufficient targeting ability, transfection efficiency, and safety, as well as an 
appropriate gene regulation system to control the level and timing of therapeutic gene 
expression. In addition, efficient manufacturing and analytical processes have to be 
developed to provide well-defined gene therapy products for clinical investigation. Over the 
past decade, significant progress was made and many technical handles in the field of gene 
therapy have been overcome. The efficiency and safety profile of delivery systems have been 
significantly improved; manufacturing processes for gene therapy products have been 
developed and optimized. These technical advances together with the increasing knowledge 
and experience in the field will undoubtedly lead to the realization of the full potential of 
gene therapy in the future.  
1.1.2 Gene Therapy Vectors 
The process of gene delivery and expression is known as transduction. In order to 
improve the efficiency of transduction in gene therapy, therapeutic genes are usually carried 
by delivery vehicles called gene therapy vectors13-15. A gene therapy vector serves several 
functions to the transgene, including (i) enabling delivery of genes into the nucleus of the 
target cells, (ii) providing protection from gene degradation, and (iii) ensuring gene 
transcription in the cell. An ideal gene therapy vector should not only be targeted and safe, 
but also protected from sequestration or immune clearance in vivo. In addition, it should be 
easily produced and purified in large amounts and at high concentrations. Given the diversity 
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of disease and tissue targets in gene therapy applications, it has become clear that there can be 
no single vector that is suitable for all applications. Many types of gene therapy vectors have 
been developed, each with their characteristic advantages, drawbacks, and applications to 
which they are best suited. These vectors fall into two broad categories: nonviral and viral 
vectors.  
The nonviral vectors consist of naked DNA delivered by injection, liposomes, 
polyplexes, nanoparticles, and other means16. Although nonviral vectors can be produced in 
relatively large amounts and are likely to present minimal toxic or immunological problems, 
presently they suffer from inefficient gene transfer. In addition, expression of the foreign gene 
tends to be transient, precluding their application to many disease states in which sustained 
and high-level expression of the transgene is required. However, as we continue to unravel 
and understand the biological mechanisms that underlie gene delivery, such as cell binding 
and entry, escape from endosomes, and nuclear import, we will be able to apply this 
knowledge to the development of more efficient nonviral vectors that may ultimately rival the 
virus-based systems.   
Viruses are naturally evolved biological machines that efficiently deliver their genetic 
materials into host cells and exploit the cellular machinery to facilitate their replication15. The 
basic concept of viral vector is to harness the virus infection pathway, but avoid the 
expression of viral genes that leads to replication and toxicity. Gene therapy viral vectors are 
being developed by genetic modification of retrovirus, adenovirus, adeno-associated virus, 
herpes simplex virus, and others17. Table 1.1 provides a summary of the main viral vectors, 
highlighting their individual properties.  
Unlike the wild type viruses, gene therapy viral vectors are engineered by deleting all, or 
some of essential viral genes that are required for the virus replication, assembling, and 
transmission, but leaving intact the cis-acting sequences that provide the viral origin of 
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replication and the signal of encapsulation. These deleted genes thus provide space in the 
vector genome for the insertion of transgene expression cassette. Such vectors lose their 
abilities to replicate in normal cells but can be produced in a complementary cell line, which 
supplies the deleted viral functions in trans.  
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Table 1.1 The main groups of viral vectors 
Vector Genetic material 
Packaging 
capacity Tropism 
Vector genome 
form Main limitations Main advantages 
Retrovirus RNA 8 kb Dividing cells Integrated 
Only transduce dividing 
cells; integration might 
induce oncogenesis in 
some applications  
Persistent gene expression in 
dividing cells 
Lentivirus RNA 8 kb Broad Integrated 
Integration might induce 
oncogenesis in some 
applications 
Persistent gene expression in 
most tissues 
adenovirus dsDNA 8 kb Neurotropic Episomal Capsid mediates a potential inflammatory response 
Extremely efficient 
transduction of most tissues 
AAV ssDNA < 5 kb Broad Episomal (>90%) Integrated (<10%) Small packaging capacity 
Non-inflammatory; 
non-pathogenic 
HSV-1 dsDNA 40 kb Broad Episomal 
Transient transgene 
expression other than 
neurons 
Large transgene capacity; 
strong tropism for neurons 
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1.1.2.1 Retroviruses  Retroviruses, particularly the murine leukemia virus (MLV), were 
among the first constructed human gene therapy vectors18. Replication-defective MLV 
vectors are generated by replacing all viral protein encoding sequences (gag, pol, env) with 
the exogenous promoter-driven transgene of interest. In addition to the packaging signal, the 
vectors retain the viral LTRs and adjacent sequences, which are essential for reverse 
transcription and integration. Retroviral vectors are propagated in the packaging cells which 
provide the structural proteins in trans. The first generation packaging cell lines expressed 
gag, pol, and env from a complete proviral DNA, lacking only the packaging signal. In order 
to reduce the risk of generating replication competent virus, newly developed packaging cells 
have the gag/pol and env located in separate constructs19, 20. 
Retroviruses have the ability to randomly integrate their genome into the host cell and 
therefore sustain transgene expression for extended time periods. This can present an 
advantage in the treatment of inherited and chronic diseases, but also a risk of insertional 
mutagenesis. The host range of MLV based retroviral vectors has been expanded by 
pseudotyping the viral envelope with the G glycoprotein from vesicular stomatitis virus 
(VSV). This modification also stabilizes the vector particles, allowing the vector stocks to be 
concentrated into high titers21. The major disadvantage of MLV based retroviral vectors is the 
inability to infect non-dividing cells, which restricts their potential applications. Other 
retroviral vectors have been developed based on lentiviruses22, 23. Lentiviruses, which are a 
special group of retroviruses including the human immunodeficiency virus (HIV), have the 
ability to infect both proliferating and quiescent cells. The transduction efficiency of lentiviral 
vectors is significantly higher than the conventional retroviral vectors. However, lentiviral 
vectors derived from HIV present obvious safety concerns.  
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1.1.2.2 Adenoviruses  Adenoviruses are non-enveloped, double stranded DNA viruses with 
a diameter of 70 nm, and a genome size of about 36 kb encoding 50 viral polypeptides. More 
than 50 different serotypes of adenoviruses are known, but the most frequently utilized for 
gene therapy are type 2 and type 5. Adenoviruses infect both dividing and nondiving cells 
with high efficiency. The key features that have made adenoviruses popular gene therapy 
vectors have been the ability to generate high-titer virus stocks and the high-level 
heterologous gene expression. 
First generation adenovirus vectors were obtained by deleting one or two viral early 
genes (E1 and E3). Cells that were transduced with these vectors expressed other adenoviral 
genes at low levels, inducing strong cytotoxic T-cell responses that rapidly eliminated 
transgene expression. Second and third generation vectors that contain additional deletions in 
other early genes (E2 and/or E4) have shown reduced toxicity in animal models24-26. The 
development of helper-dependent adenoviruses (HD-Ads) that are deleted for all viral genes 
has been the most important advance to decrease immunogenicity, prolong transgene 
expression and improve the prospects of adenovirus vectors for long-term gene therapy27. 
1.1.2.3 Adeno-associated virus  Adeno-associated virus (AAV) belongs to the parvoviruses. 
It is a single-stranded, non-enveloped DNA virus of 4.5 kb size. Most AAV vectors have been 
derived from AAV2, but, so far, a total of eight distinct AAV serotypes have been identified 
that infect different cell types with different efficiencies28-30. Wild-type AAV 2 is 
non-pathogenic and capable of integrating into the long arm of chromosome 19 after 
infection of human cells31. Recombinant AAV 2 vectors are generated by insertion of a 
therapeutic gene between two inverted terminal repeats (ITRs), replacing all coding 
sequences except ITRs32. The vector genome can be rescued by supplying rep and cap 
proteins in trans from a packaging plasmid, together with a helper virus (usually adenovirus 
or herpes simplex virus) infection33.  
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Adeno-associated viral vectors have been shown to transduce a broad range of cells 
through both episomal transgene expression and by random chromosomal integration. The 
integration property of AAV vector enables it be used for long-term transgene expression in 
non-dividing cells. However, there are some disadvantages associated with the application of 
AAV. The packaging capacity is relatively restricted and the large scale production inefficient. 
In addition, the integration into the host genome is random, which can lead to unexpected 
activation or inhibition of endogenous gene expression. 
1.1.2.4 Herpes simplex virus type 1  HSV-1 is the largest and most complex of all the 
viruses described here. One important feature of this vector is its capacity to carry large 
fragments of foreign DNA. Replication-defective HSV-1 vectors can carry up to 40 kb of 
foreign DNA, facilitating the delivery of several separate expression cassettes, or large single 
genes. Wild type HSV-1 is a neurotropic virus that can establish lifelong persistence in 
sensory neurons. This natural tropism has made neuropathological disorders one of the most 
promising applications of replication-defective HSV-1 vectors. The next session summaries 
the basic biology of HSV-1, the construction of HSV-1 vectors, and the use of HSV-1 vectors 
for the treatment of neurological diseases in animal models. 
1.2 HERPES SIMPLEX VIRUS TYPE 1 VECTOR 
1.2.1 Basic Biology of HSV-1 
 Herpes simplex virus type 1 (HSV-1) is an enveloped double-stranded DNA virus of 
about 200 nm in diameter. Mature HSV-1 virion consists of a 150Kb DNA genome encased 
in an icosahedral capsid. A lipid envelope, obtained from the infected host cell, surrounds the 
virus particle. This envelope is studded with at least 10 different types of viral glycoproteins 
(gB-gE, gG-gJ, gL, and gM) that serve principally to mediate virus entry into host cell.  
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Between the capsid and the envelope, there is an amorphous layer called the tegument, which 
contains a number of proteins that are responsible for the induction of viral gene expression 
and shutoff of host protein synthesis (reviewed in 34).  
Entry of HSV-1 into the host cell is mediated by glycoproteins embedded in the viral 
envelope. Two different steps of this process can be identified: attachment to the cell surface 
and fusion of the viral and cellular membrane resulting in viral entry. The virus is also 
capable of infecting neighboring cells by moving transcellularly across cell membranes, a 
process referred to as lateral spread. HSV-1 infection is initiated with adsorption of virion on 
permissive cell surface via binding to cell surface glucosaminoglycan (GAGs), primary 
heparan sulfate (HS) but also dermatan sulfate mediated by exposed domain of gC and 
gB35-37. Together this binding activity represents about 85% of the binding activity to Vero 
cells with gC contributing the majority35. The rest of the binding activity is thought to be 
contributed by other glycoproteins binding to other receptors. Following the initial adsorption 
event, a secondary binding event occurs between gD and cellular receptors. Three classes of 
gD receptors have been identified. They include HveM or HveA, a member of the tumor 
necrosis factor receptor family38; nectin-2 (HveB) and nectin-1 (HveC), two members of the 
immunoglobulin superfamily39; and 3-O-sulfated HS40. Binding of gD to its cognate receptors 
not only secures the adsorption of the virus on cell surface, but also initiates the fusion of the 
virus envelope with the cellular membrane and subsequent virus entry. The detailed 
mechanism of the membrane fusion and entry is obscure. However, it is known that gB, gD, 
and gH/gL complex are necessary in this event. One hypothesis of the entry mechanism is 
that the binding of gD to one of its receptors results in a conformational change in gD, 
enabling its interaction with gB or gH/gL and activation of membrane fusion. gB, gD, gH, 
and gL are thus essential for viral infection41. 
 
 9
Following cell entry, HSV-1 genes are expressed in a tightly regulated, interdependent 
temporal cascade42. Transcription of the five immediate-early (IE) genes, ICP0, ICP4, ICP22, 
ICP27 and ICP47, commences on viral genome entry to the cell nucleus. Expression of IE 
genes proceeds in the absence of de novo viral protein synthesis, and is regulated by 
promoters that are responsive to a viral tegument protein VP1643, 44. Expression of IE genes 
initiates a cascade of viral gene expression, beginning with the transcription of early (E) 
genes, which primarily encode enzymes involved in DNA replication. In the presence of IE 
gene products and viral DNA synthesis, the late (L) genes are expressed. The late genes 
mainly encode structural components of the virion. Following translation of the late gene 
products, viral genomes are packaged into the newly assembled capsids. Tegument proteins 
then accumulate around the capsids. Finally, lipid membrane envelopes containing 
viral-encoded glycoproteins are acquired during the immature virus budding through the 
cellular membrane system and mature HSV-1 virions are released (reviewed in 34).  
Primary infection of wild type HSV-1 on epithelial cells of skin or mucous membrane 
usually results in a lytic viral replication cycle as described above. Viruses released at the site 
of the primary infection may enter local sensory nerve terminals. The virus is then 
transported through the axon in a retrograde way to the neuronal cell body in the peripheral 
sensory ganglion45. In the neuron, HSV-1 may enter into another lytic replication cycle, 
which will result in neuronal cell death and egress of infectious particles. Alternatively, the 
viral DNA may enter into a latent state in which the viral genome persists as stable episomal 
element, sometimes for the lifetime of the host46. During latency, the cascade expression of 
IE, E and L genes is silenced. However, a set of nontranslated RNA species designated as 
latency-associated transcripts (LATs) is produced47, 48. No viral particles or any detectable 
viral proteins are found in latently infected ganglia in vivo. The latent HSV-1 genome can be  
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reactivated when the host-virus balance is disturbed49. The virus reactivation results in lytic 
virus replication and recrudescence of the disease in the same dermatomal distribution as the 
original infection. 
1.2.2 The Construction of HSV-1 Vectors 
Based on different approaches to eliminate the viral toxicity, three types of HSV-1 
vectors have been constructed.  
1.2.2.1 Amplicon vectors  The HSV-1 amplicon is a plasmid DNA that contains a transgene 
cassette and two viral sequences, the HSV-1 packaging sequence, and an HSV-1 origin of 
replication, the oris sequence50-52. Thus, the toxicity of HSV-1 amplicon is maximally reduced 
by the deletion of essentially all virus-coding genes. HSV-1 amplicon vectors can be 
generated by cotransfection of eukaryotic cells with the amplicon plasmid and bacterial 
artificial chromosome (BAC) containing an HSV-1 genome, but devoid of the packaging 
signals and the origin of replication53, 54. HSV-1 structural proteins expressed from the BAC 
in cells form building blocks that package the concatermeric amplicon plasmids. Thus, the 
mature amplicon particles possess the same protein structure as the wild type HSV-1 viruses. 
The HSV-1 BAC is a recent advance on the prior amplicon generation methods using a set of 
HSV-1 cosmids or a helper virus. Although HSV-1 amplicons could be used to express genes 
in a variety of eukaryotic cells including neuron, their use as gene therapy vectors is limited 
by the fact that the production of high titer amplicon stock free of replicating helper virus is 
extremely difficult.  
1.2.2.2 Conditionally replicating vectors  This type of HSV-1 vectors are created by the 
deletion of some non-essential viral genes so that the mutants retain the ability to replicate in 
vitro but are comprised in vivo, in a context-dependent manner55. For example, HSV-1 
mutants lack of the genes encoding thymidine kinase (TK) or ribonucleatide reductase (RR) 
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are replication defective in neurons, in which the virus needs to synthesize its own DNA 
precursors56, 57. However, this mutant retains the ability to undergo lytic replication in rapidly 
dividing cells, such as cancer cells. In vivo, viruses that are null of ICP34.5, either alone or in 
combination with RR, have been shown to replicate selectively in rapidly dividing malignant 
cells and have been developed as oncolytic agents57, 58. The ICP34.5 mutants have been 
studied in phase I clinic trial for the treatment of brain cancer57. Although the conditionally 
replicating vectors appear non-toxic at present, it is not yet clear whether these therapeutic 
agents are efficacious.  
1.2.2.3 Replication defective vectors  Replication defective HSV-1 vectors have been 
developed by the deletion of the essential immediate early genes (ICP4 and ICP27) 59-62. 
Deletion of these genes prevents progression of viral gene expression from the immediate 
early to the early phase, thus blocking the lytic viral replication cycle. Infection of this type of 
vectors in vivo results in a state this is very similar to latency63. The genomes may persist for 
long period in neuronal or non-neuronal cells. The replication defective vectors can be 
efficiently produced in complementing cell lines that provide the deleted viral function in 
trans. Vectors deleted of ICP4 and ICP27 may be still toxic, due to the expression of other IE 
gene products. HSV-1 vectors of less toxicity can be created by the deletion of more IE genes 
or other essential viral genes62. These replication defective genomic vectors may be the best 
currently attainable compromise between minimizing toxicity and maximizing production.  
1.2.3 Applications of HSV-1 Vectors to Diseases of the Nervous System 
Many diseases of the nervous system are chronic. Effective gene therapy for these 
diseases will depend on delivery of appropriate therapeutic genes to a relevant population of 
neurons or glia, followed by long-term transgene expression. Replication defective HSV-1 
vectors are extremely attractive for the treatment of neurological diseases because of their 
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natural neurotropism and the propensity of the virus to remain latent for the duration of the 
host lifetime. Direct inoculation of these vectors into neural parenchyma is effective in rodent 
models of brain tumor, Parkinson disease, spinal cord injury, and spinal root trauma. 
Subcutaneous inoculation of the HSV-1 vectors can be used to transduce neurons of the 
dorsal root ganglion to provide a therapeutic effect in models of polyneuropathy and chronic 
regional pain. The preclinical applications of HSV-1 vectors in animal models of neurological 
diseases have been reviewed by Glorioso64, 65 and Burton8, 66, 67. In human trials, direct 
injection of replication-competent HSV-1 into brain tumors has proven safe57. Human trials 
of replication defective HSV-1 vectors by direct inoculation for treatment of glioblastoma and 
HSV-1 gene transfer by subcutaneous inoculation for the treatment of chronic intractable pain 
should commence soon.    
1.3 VIRAL VECTOR MANUFACTURING 
1.3.1 Viral Vector Production from Cell Culture 
The clinical implementation of gene therapy requires large scale production of viral 
vector stocks derived from packaging cell lines. In general, the efficiency of vector 
production depends on the vector itself, the complementary cell line, and the cell culture 
conditions.  
As mentioned earlier, some genes that are essential for virus replication in host cells are 
deleted in viral vectors. The deleted genes are stably transfected into packing cell lines to 
support vector growth. However, the productivity of these crippled viruses in packing cell 
lines is usually significantly lower than that of wild type viruses, and it depends heavily on 
how well the packaging cell lines complementarily provide the deleted viral gene products in  
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trans. Therefore, packaging cell lines for vector production should be strategically developed 
to optimize the expression kinetics of the viral genes so as to achieve high level of viral 
vector production.  
In addition, cell culture parameters, such as temperature, multiplicity of infection, 
passage number, medium components and serum concentration, level of inhibitory metabolic 
by-products, and culture confluency at time of infection, will also affect the vector yield. It is 
expected that the advances in cell culture engineering, cell metabolism, bioreactor design and 
operation, will all positively impact the efficient production of viral vectors. Recent advances 
include the removal of serum from the culture medium, the implementation of suspension 
culture (either by the development of anchorage-independent cell line or through the use of 
micro-carriers), and the development of more efficient bioreators or cell culture operation 
models. 
1.3.2 Viral Vector Purification 
Viral vectors produced from packaging cell lines are invariably contaminated with host 
cell proteins and DNA, as well as other substances introduced in the manufacturing process. 
Elimination of these contaminants from viral vector preparations is helpful to improve the 
transduction efficiency. Further, the high purity specifications are strictly required by the 
regulatory agencies for the clinical application of viral vectors. In this sense, efficient and 
scaleable purification processes of high yield are essential for the advancement of gene 
therapy into clinic.  
1.3.2.1 Harvesting, clarification, and concentration  At end of viral vector propagation in 
packaging cell lines, the vectors will be either located intracellularly or extracellularly 
(through active release or lysis). This feature of viral vectors determines the method to be 
used to for their harvesting, clarification and concentration.  
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Retrovirus (including lentivirus) vectors are actively secreted into the culture medium 
without causing cell lysis. Therefore there is no need to intentionally break up the packaging 
cells to release the vectors during harvesting. Adenovirus and AAV are lytic viruses, yet the 
majority of vector particles will remain within the cells after the completion of vector growth. 
Physical methods such as freezing-and-thawing and sonication are usually employed to 
further break up the cells and release the intracellular vectors. For HSV-1, vector particles 
that remain within the cells are unlikely to have reached a sufficiently mature state for 
harvesting. Among the extracellular HSV-1 particles, a large fraction remains closely 
associated with the outer membrane of the host cells. Buffers containing high concentration 
of salt can be introduced into the harvest to release the cell-associated HSV-1 vectors into the 
culture medium. 
After harvesting, the first processing operation in a viral vector purification train will be 
a solid-liquid separation step that is aimed at recovery of cells enriched with intracellular 
products (adenovirus and AAV vector), or to eliminate cells and debris from the supernatant 
that is enriched in extracellular products (retrovirus and HSV-1 vector). In laboratory scale, 
such clarification step is usually achieved by centrifugation, due to its ease of implementation. 
However, centrifugation process is hard to scale up and the centrifuges used for large scale 
operation are usually very expensive. Membrane filtration in dead-end or cross-flow modes 
provides a more efficient way for solid-liquid separation and it is easy to scale up. We have 
developed a tangential flow filtration process to clarify cell debris from HSV-1 vector 
preparations68. Over 90% of HSV-1 vectors in the supernatant can be recovered after 
clarification through a cartridge of hollow fiber membranes of 0.8 μm pore diameter. 
Membrane filtration processes for the clarification of retrovirus and lentivirus preparations 
have also been reported69, 70.  
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Following the clarification, a concentration step is typically employed to diminish the 
necessary scale of subsequent operations and to increase the kinetic driving force for the 
subsequent purification. The concentration of conventional viral vaccines by precipitating or 
centrifuging the viral particles into solid pellets is commonly undertaken, but some loss of 
infectivity of the vectors during the phase change appear to have restricted application of 
these methodologies for gene therapy vectors. In contrast, tangential flow filtration involves 
no phase change. This process concentrates the viral vectors in retentate and pemeates water 
and low molecular weight impurities. Kuiper et al. used a 0.3 m2, 100 kDa molecular weight 
cut-off Sartocon ultrafiltration module to concentrate moloney murine leukemia viral vector69. 
The process was conducted in a diafiltration mode to wash out protein and DNA impurities. 
About 160 fold concentration was achieved with an average of 77±14% infectious virus 
recovery. The concentration of lentivirus vectors by tangential flow ultrafiltration (TFF) was 
studied by Geraerts et al70. TFF allowed a 66-fold concentration of the vectors with complete 
vector recovery. 
1.3.2.2 Purification  Impurities in the clarified and concentrated viral vector preparations 
will be extensively removed in the subsequent purification steps. Traditionally, viral vectors 
have been purified by CsCl gradient centrifugation, which is both time and labor intensive, 
and is not amenable to scale up. In addition, in order to achieve a high degree of purity, it was 
necessary to perform double or multiple rounds of CsCl centrifugation. The lengthy exposure 
of viral vector to high salt concentration may result in gradual inactivation of the vector. For 
example, Auricchio et al. documented that the infectivity of AAV vector decreased by a factor 
of 2 every 24 hr the virus was incubated in CsCl71. Moreover, gradient centrifugation may not 
remove particular contaminants that have size and density properties very close to those of  
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the viral particles. Replacing the gradient centrifugation in viral vector purification with a 
more efficient and scaleable purification method such as column chromatography will 
provide more efficient and cost-effective vector purification.  
Chromatography procedures based on ion exchange, affinity, and size exclusive 
interactions have been used for viral vector purification. The choice of chromatography mode 
in a particular case depends on the biochemical properties of the viral vector and the stage of 
purification. If necessary, a sequential combination of chromatography steps based on 
different interaction modes will be implemented to achieve the required purity. 
Ion exchange chromatography separates molecules based on the differences of overall 
charges of the molecules. For viral vector purification, ion exchange chromatography can be 
carried out in either retention or flow-through mode. In the retention mode, the viral vectors 
will bind to the ion exchange column and the impurities will pass through the column. In the 
flow-through mode, the viral vectors will pass through the column with the retention of 
impurities. The advantages of ion exchange include its versatility and flexibility. However, 
the specificity of ion exchange may not be high enough to allow sufficient purification in a 
single chromatography step.  
Ion exchange chromatography has been used for AAV vector purification. Zolotukhin et 
al. used Q-Sepharose anion exchange chromatography to purify AAV serotype 1, 2, and 5 
preparations that were previously partially purified by iodixanol gradient centrifugation72. 
The purified vector stocks after ion exchange are 99% pure with titers of 1*1012 to 1*1013 
vector genomes/ml. Smith et al. developed a process combining anion-exchange and size 
exclusion chromatography (SEC) to purify AAV 5 particles to near homogeneity30. (SEC or 
gel filtration chromatography separates biomolecules on the basis of differences in molecular 
size. Large molecules are excluded from pores and are eluted prior to smaller ones.) In the 
process developed by Smith et al., AAV particles were directly captured on a Mono-Q anion 
 17
exchanger from cellular extracts at pH 6. The AAV particles eluted from the anion exchange 
column were further purified on a Superdex 200 gel filtration column, which has an exclusion 
limit for globular proteins of approximately 1.3*106 Da30. Kaludov et al. described a process 
involving the capture of AAV 5 followed by additional purification and concentration using a 
centrifugal filtration device73. Davidoff et al. utilized cation exchanger to capture impurities 
from the AAV 8 preparation74. The AAV8 particles that passed through the cation exchanger 
were then captured on an anion exchanger. Elution of the bound AAV 8 from the anion 
exchanger using high salt concentration resulted in an AAV preparation that has greater than 
90% purity.   
The adenovirus particle has an acidic pI. As such anion exchange resins have been 
shown to selectively bind adenovirus particles from contaminating cellular components and 
free viral proteins/DNA. Anion exchange as the sole chromatographic step usually fails to 
produce adenovirus with purity to or better than 2 X CsCl gradient centrifugation. Therefore, 
a polishing step is necessary. The studies by Huyghe et al. present data on the use of anion 
exchange as a capture step and immobilized metal affinity chromatography (IMAC) as a 
polishing step75. Blanche et al. demonstrated the utility of anion exchange to produce 
high-quality adenovirus21. Kamen used Fractogel EMD DEAE-650 anion exchanger to 
capture adenovirus vectors and utilized a gel filtration step to finish the polishing step76. As 
an alternative polishing step, Green et al. proposed use of a PolyFlo flow-through 
chromatographic method to remove additional host and viral proteins not removed in the first 
anion-exchange step77. 
Ceramic hydroxyapatite comprises functional groups of positively charged pairs of 
calcium ions and clusters of negatively charged phosphate groups. Therefore, it combines  
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both cation exchange and anion exchange in one column. Hydroxyapatite adsorptive 
chromatography was found to purify wild-type inactive MoMLV30 as well as recombinant 
retroviral vectors69, with moderate recovery of infectious particles (18–31%).  
Affinity chromatography is a technique enabling purification of a biomolecule with 
respect to individual chemical structure. The substance to be purified is specifically and 
reversibly adsorbed to a ligand, which is immobilized by a covalent bond to a 
chromatographic matrix. In comparison to ion exchange, affinity chromatography usually has 
a higher selectively and efficiency. Sometimes, one-step purification can be achieved from 
affinity purification. 
Heparin and the structurally related heparan sulfate belong to the family of 
glycosaminoglycans (GAGs) which are linear anionic polymers made up of repeating 
disaccharides units of glucosamine and uronic acid. The ubiquitously distributed cell surface 
heparan sulfate serves as receptor for several viruses, such as AAV2 and HSV, to bind to and 
gain access to susceptible cells. Heparin affinity chromatography proved to be a powerful 
tool for the purification of AAV2. Zolotukhin demonstrated the use of heparin affinity 
chromatography to purify AAV2 stock from iodixanol gradient centrifugation78. Harnessing 
the high selectivity of heparin chromatography, Auricchio developed single-step gravity-flow 
heparin affinity purification for AAV271. The purity of AAV2 prepared from gravity-flow 
heparin affinity chromatography was higher than that from 2X CsCl gradient centrifugation, 
yet the latter technique required much more time and labor. O'Keeffe et al. investigated 
different heparin functionalized matrixes for the purification of herpes simplex virus 2 
vaccine. They found that HSV2 vaccine exhibited substantial adsorption on heparin HP 
matrix79. The adsorbed vaccine particles could be completely recovered from the matrix with 
1.5 M NaCl buffer to provide a purified preparation containing only 0.05 pg protein/pfu and 
1.2 x 10-4 pg DNA/pfu. Segura et al. demonstrated the use of heparin chromatography for the 
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purification of VSV-G pseudo-typed moloney murine leukemia virus80. Intact, infective 
retroviral particles were recovered by elution with low salt concentrations (350 mM NaCl). A 
purification factor of 63 with a recovery of 61% of functional retrovirus particles was 
achieved using this single step.  
Another example of receptor affinity purification for viral vectors was demonstrated by 
Auricchio et al., who isolated AAV5 vectors by a single-step chromatography through a 
mucin affinity column81. The rationale for developing this method was based on the 
observation that 2,3-linked sialic acid is required for AAV5 entry82.  
Although simple and effective, receptor affinity purification relies on the specific 
interaction of a particular viral vector with its cell surface receptor. Because of the specificity, 
the affinity ligand used for purifying one viral vector may not be applicable to others. For 
example, heparin affinity chromatography is not an effective purification method for AAV 
serotypes 1, 5, and 8, which do not use heparan sulfate as receptors. Moreover, for many 
viruses, their entry receptors are either unknown or too expensive to be used as ligands for 
purification. Thus, inexpensive generic affinity ligands that bind to different types of viral 
vectors will be promising for viral vector purification. 
1.4 IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY 
Transition metal ions used in immobilized metal affinity chromatography (IMAC) are 
classified as generic affinity ligands since specific biological binding sites of proteins are not 
necessary involved. In contrast, coordination interactions between transition metal ions and 
protein surface electron donating groups form the basis of IMAC separation83. Typically, the 
metal ions, such as Cu2+, Zn2+, Ni2+, Co2+, or Fe3+, are immobilized on a chromatographic 
support through coordination with chelating molecules such as iminodiacetate (IDA) or 
nitrilotriacetate (NTA), which are covalently attached to the support. Amino acids histidine, 
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tryptophan, and cysteine which contain electron donating imidazole and thiol groups are 
primarily responsible for the binding of proteins to immobilized metal ions83. Factors such as 
the accessibility, micro-environment of the binding residue, co-operation between 
neighboring amino acid side groups, and local conformations play important roles in the 
strength of binding and thus protein retention84. Elution of the bound proteins is 
accomplished by passing solution containing increasing concentration of hydrogen ions or 
imidazole. Hydrogen ions compete with the immobilized metal ions for the binding site on 
the protein while imidazole competes with proteins for the immobilized metal ions. After 
gradient elution, the metal ions and strongly bound proteins can be stripped from the column 
by passing a solution of ethylene diamine tetraacetic acid (EDTA), which is a strong chelating 
agent. Low cost of operation, ease of regeneration of the matrix and relatively high specificity 
of protein-metal interaction are among the key advantages of IMAC.  
Since its introduction by Porath in 197585, IMAC has been used for the purification of a 
wide variety of proteins displaying favorable metal binding characteristics86, 87. When a 
protein lacks the prerequisites for retention on IMAC columns, genetic modifications that 
fuse the protein to a metal binding peptide (referred to as affinity tag) may endow the protein 
with increased metal binding affinity. One commonly used affinity tag is the sequence 
comprised of six adjacent histindine residues (His6)88, 89. Literature reports also describe the 
purification of fusion proteins using other affinity tags that display different levels of metal 
affinity90-92. The level of affinity a desired protein should have for a chelated metal ion should 
be dictated by the relative affinity of the cellular proteins of the host cell used for expression 
of that protein93. An affinity tag of appropriate affinity is the one that will direct the elution of  
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the fusion protein to the region of the elution profile where the elution of DNA and host cell 
proteins are minimal and the expression and activity of the fusion product are not 
compromised. 
Recently, the application of IMAC has been extended to the purification of gene therapy 
viral vectors. This study describes the development of immobilized cobalt affinity 
chromatography for the selective purification of HSV-1 vectors engineered with cobalt 
affinity tags. During the progress of this project, IMAC purifications for AAV94, adenovirus75, 
retrovirus95, have been reported. 
1.5 REACTIVE OXYGEN FREE RADICALS AND METAL CATALYZED 
OXIDATION 
Free radicals are defined as chemical species capable of independent existence that 
contains one or more unpaired electrons. Dioxygen (O2) in its ground state, 3∑g-, is a 
biradical since it has two unpaired electrons each located in a different π* antibonding orbital. 
These unpaired electrons spin in the same direction (“triplet” ground state), rendering 
dioxygen rather unreactive toward other molecules existing in “singlet” ground state with 
paired electrons. Thus, the chemistry of dioxygen, except for the excited singlet state 1Δg and 
1∑g+, is favored by free radical reactions with the sequential acceptance of electron one at a 
time.  
In the sequential electron-transfer process where O2 undergoes reduction, several 
reactive intermediates are formed, such as superoxide (O2•-), hydrogen peroxide (H2O2), and 
the extremely reactive hydroxyl radical (•OH): collectively termed as the reactive oxygen 
species (ROS)96-99. The process can be presented as: 
OHOHOHOO 2ee22e
-
2
e
2
---- ⎯→⎯⋅⎯→⎯⎯→⎯⎯→⎯ • . 
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1.5.1 Generation of reactive oxygen free radicals 
Oxidative free radicals are generated during normal cellular metabolism100. During 
oxidative phosphorylation, the mitochondrial cytochrome oxidase enzyme system links 
production of ATP to controlled tetravalent reduction of dioxygen to water. In this process, 
the ROS intermediates are tightly bound to the active sites of the enzymes. Numerous 
cytosolic enzymes can produce ROS outside the mitochondrial membranes. Those unbound 
ROS can disrupt normal functioning of the cell in disease states where the cellular antioxidant 
systems are impaired. Enzymes that catalyze univalent reduction of dioxygen to superoxide 
anion radical include xanthine oxidase, aldehyde oxidase, dihydrorotic dehydrogenase, flavin 
dehydrogenases, and peroxidases. A major source of hydrogen peroxide in cell is the 
dismutation of superoxide anion radical by the superoxide dismutase enzymes (SOD). 
Hydroxyl radicals are formed in the Fenton reaction whenever hydrogen peroxide comes into 
contact with transition metal ions101. In addition, the respiratory burst during phagocytic 
activity generates all forms of ROS essential for the host defense against invading 
microbes102.  
Outside the living systems, transition metal catalyzed oxidation is an important pathway 
that leads to the ROS generation103-105. Many transition metals such as Co, Cu, Fe, and Ni, 
which exist in several spin states, can function as catalysts to sequentially transfer electrons 
from electron donors to dioxygen. Normally, transition metals in their oxidized states (i.e., 
Co3+, Cu2+, Fe3+, Ni3+) do not react readily with dioxygen to generate a more reactive oxygen 
species. An electron donor or reducing agent is needed to reduce the transition metal ion106. 
This reduced form may then interact with dioxygen to generate ROS107. Typically, as 
illustrated in Eqs.1 & 2, the reduced form of transition metal ion, complexed by appropriate 
ligands, may donate an electron to reduce dioxygen to form superoxide anion radical. In these 
equations, Cx represents a complex that may include chelating molecules, solvent, reducing 
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agent, etc. Superoxide anion radical may acquire another electron from the reduced form of 
transition metal ion to form hydrogen peroxide (Eqs. 3). It is also possible that hydrogen 
peroxide is generated directly without the superoxide intermediate.  
O2 + CxMn+ → CxMn+-O-O• → CxM(n+1)+-O-O-      (1) 
CxM(n+1)+-O-O- →CxM(n+1)+ + O2•-         (2) 
CxMn+ + O2•- + 2H+ → CxM(n+1)+ + H2O2        (3) 
The reactivity of either superxide anion radical or hydrogen peroxide by itself to other 
molecule is rather low. However, in the presence of transition metal ions, they are converted 
to highly reactive hydroxyl radical via Fenton (Eqs. 4) or Haber-Weiss reaction (Eqs. 6) 
 CxMn+ + H2O2 → CxM(n+1)+ + OH- + •OH        (4) 
CxM(n+1)+ + O2•- → CxM(n)+ + O2          (5) 
H2O2 + O2•-→ O2 + OH- + •OH          (6) 
It is of note that Eqs. 6 is the combination of Eqs. 4 and Eqs. 5. Eqs. 3 and Eqs. 6 indicate that, 
depending on the reaction conditions, O2•- may serve as either the reductant or oxidant of the 
metal ion.  
 The ligand with which the transition metal ion is complexed has a profound effect on the 
oxidative activity of transition metal ions. It may either enhance or inhibit the dioxygen 
activation. For example, activity of Fe2+ is enhanced by EDTA or nitrilotriacetic acid (NTA), 
but inhibited by o-phenanthroline and deferoxamine108. Unchelated Ni2+ reacts with H2O2 
only very slowly. However, its reactivity toward H2O2 and other oxygen species may be 
greatly accelerated by oligopeptides or proteins109, 110. Likewise, Co2+, stable under air, 
becomes sensitive to oxidation with atmospheric O2 in the presence of organic ligands111, 112.  
 24
1.5.2 Oxygen free radical mediated damage to biomolecules 
 The highly reactive free radical intermediates can cause irreversible oxidative damages to 
proteins 113, 114, nucleic acids 115, 116, and lipids 117, 118 in the cell, resulting in deleterious 
biological consequences such as aging 118, carcinogenesis 116 and other disease states 119, 120. 
In addition, metal catalyzed free radical generation in vitro is an important pathway that leads 
to the inactivation, modification, or degradation of biological products during bioprocessing, 
transport, and storage 121.  
 ROS from metal catalyzed oxidation cause protein damage such as fragmentation, 
carbonyl formation, and oxidative modification of amino acid residues114. It is important to 
note that the oxidative free radical intermediates react immediately with the amino acids at 
the metal-binding site before diffusion into bulk solution. This feature makes metal catalyzed 
oxidation a site-specific process104. The amino acid residues most susceptible to metal 
catalyzed oxidation are Cys, His, Arg, Lys, and Pro. The sulfhydryls of Cys are commonly 
oxidized to disulfides, but they may be turned into sulfino- sulfeno-, and solfono- derivatives 
as well. The His imidazole may be oxidized to aspartic acid, asparagines, or 2’-OH-His. Arg 
is converted to γ-glutamic-semialdehyde; Lys, to 2-amino-adipic-semialdehyde; and Pro is 
turned into glutamic acid, pryoglutamic acid, γ-aminobutyric acid, and 
γ-glutamic-semialdehyde. Glutamic and aminoadipic semialdehydes are the main carbonyl 
products of metal catalyzed oxidation of proteins. The oxidative free radicals could also cause 
intra- or inter-protein cross-linking. Because of this, proteins also may become cross-linked 
with DNA.  
Although loss of activity of protein is a sensitive and vital indicator of protein damage, it 
does not necessarily reflect all forms of damage, nor does it elucidate the nature of the 
damage. SDS-PAGE is a common method for measuring fragmented or cross-linked proteins, 
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while amino acid analysis or peptide mapping can used to measure chemical modification. 
Another important indication of protein damage is an increased sensitivity to digestion by 
proteolytic enzymes such as chemotrypsin or trypsin. A damaged protein with increased 
proteolytic susceptibility but retained biological activity might have a decreased half-live in 
vivo 122.  
ROS can also cause oxidative damage to DNA: both nuclear and mitochondrial. The 
nature of such damage includes mainly base modification, deoxyribose oxidation, strand 
breakage, and DNA-protein cross-links. Among the various ROS, •OH generates various 
products from the DNA bases which mainly include C-8-hydroxylation of guanine to form 
8-oxo-7, 8 dehydro-2’-deoxyguanosine, a ring-opened product; 2, 
6-diamino-4-hydroxy-5-formamimodipyrimidine, 8-OH-adenine, 2-OH-adenine, thymine 
glycol, cytosine glycol, etc123. ROS-induced DNA damages include various mutagenic 
alterations as well. For example, mutation arising from selective modification of G:C sites 
specially indicates oxidative attack on DNA by ROS124. 
Oxidative free radicals catalyze the oxidative modification of lipids. While lipid 
peroxidation is not initiated by O2•- and H2O2, the generation of •OH in the presence of 
transition metals results in the initiation of lipid peroxidation125. This can lead to a 
propagation process since peroxy radicals are both the products of lipid peroxidation as well 
as reaction initiators. Lipid peroxy radicals react with other lipids, proteins, and nucleic acids. 
Cell membranes, which are structurally made up of large amounts of polyunsaturated fatty 
acid, are highly susceptible to oxidative attack. As a consequence, changes in membrane 
fluidity, permeability, and cellular metabolic functions may result. 
During IMAC purification, immobilized transition metal ions contact a wide variety of 
compounds in the mobile phase, which may include dissolved oxygen and reducing agents 
from cell culture. Thus, there are possibilities that the metal ions could trigger free radical 
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generation and cause damage to the biological product upon purification on IMAC. However, 
in contrast to the large body of literatures that address metal catalyzed oxidation in solution, 
the metal catalyzed oxidation of biological products in IMAC has not been well recognized. 
This study describes the inactivation of HSV-1 vector by •OH radicals when it is purified on 
immobilized cobalt affinity column. The virus inactivation could be substantially reduced by 
the inclusion of free radical scavenger such as ascorbate in the chromatographic mobile phase. 
This finding is the first demonstration of oxygen free radical mediated biological inactivation 
in an actual IMAC purification and an effective method to prevent it.  
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2.0 MATERIALS AND METHODS 
2.1 VIRUSES AND CELLS 
All viruses were derived from KOS strain of HSV-1. Vector QOZHG126 (derived from 
d10663, 127) was used as the untagged virus in the initial IMAC study. The d106 vector (kindly 
provided by Neal DeLuca, Univeristy of Pittsburgh) has deletions of the essential immediate 
early (IE) genes ICP4 and ICP27. Two other IE genes, ICP22 and ICP47 have mutations in 
their promoters such that they are expressed as early genes. The ICP27 deletion was replaced 
with a human cytomegalovirus (HCMV) IE gene promoter driving a green fluorescence 
protein (GFP) reporter gene cassette. The UL41 gene was disrupted in d106 by the insertion 
of HSV-1 ICP0 IE promoter driving a lacZ expression cassette to produce the QOZHG. The 
QOZHG vector was propagated in 7B cells61, 128, a Vero cell line stably transfected with ICP4 
and ICP27. HSV-1 mutant K082129 (gift from Dr. Stan Person, Johns Hopkins University) 
was used as backbone virus to construct the gB tagged virus KgBHAT. The gB gene of K082 
harbors an HpaI linker insertion that introduces a chain terminator codon at gB amino acid 
residue 43. K082 virus produces no gB-specific polypeptide and can only grow in the gB 
expressing Vero cell line, D6 (also a gift from Dr. Stan Person). Once constructed, KgBHAT 
was propagated in Vero cells. The KgBpK- control virus35, in which the heparan sulfate 
binding of gB was deleted, was propagated on Vero cells. All cell lines were maintained at 
37oC in Dulbecco’s modified essential medium (DMEM: Life Technologies Inc. Gaithersburg, 
MD) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 100 U/ml 
penicillin/streptomycin (all media supplements were supplied from Life Technologies Inc). 
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2.2 CONSTRUCTION OF gB MUTANT PLASMID 
Plasmid pgBHAT was constructed by inserting in frame the sequence encoding the cobalt 
affinity peptide tag (HAT) 90 within a plasmid (pTZ18UgBpK-) encoding a mutant form 
HSV-1 gB (UL27). Plasmid pTZ18UgBpK- was previously constructed by us35, in which the 
27 nucleotides encoding the heparan sulfate binding domain of gB (amino acid 68-76 
[KPKKNKKPK]) was replaced by an in-frame BamHI site for future cloning. The 
synthesized oligonucleotides encoding HAT (HAT amino acid sequence: 
KDHLIHNVHKEEHAHAHNK90) were designed (sense:5’GATCTGAAGGATC 
ATCTCATCCACAATGTCCACAAAGAGGAGCACGCTCATGCCCA CAACAAA-3’ and 
anti-sense: 3'-ACTTCCTAGTAGAGTAGGTGTTACAGGTGTTTCTCCTCGTGCGA 
GTACGGGTGTTGTTTCTAG-5’) to be flanked by BglII sticky ends (Fig. 5). The 
oligonucleotides (10 pM) were mixed in PBS, denatured at 100oC for 10 min and then 
annealed for 1 h. BamHI digested plasmid pTZ18UgBpK- DNA was dephosphorylated, gel 
purified, and then ligated with the annealed HAT coding oligonucleotide mixture and then the 
ligation mixture was transformed into DH5α competent cells (Invitrogen, Carlsbad, CA). 
Single colonies from the transformation were cultured and plasmid DNA extracted using the 
Qiagen Quick Plasmid Kit (Qiagen, Valencia, CA). Clones containing HAT inserts were 
screened for the lack of a BamHI site and the orientation of HAT coding sequence was 
confirmed by DNA sequencing analysis (forward primer: 5’-CTCTTGGGGTTGACGCT 
GGGGG-3’, reverse primer 5’-GTTTGCATCGGTGTTCTCC GCC-3’) in University of 
Pittsburgh Molecular Medicine Institute DNA sequencing core facility.  
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2.3 CONSTRUCTION AND ISOLATION OF gB TAGGED HSV-1 MUTANT 
To construct the gB tagged virus KgBHAT, plasmid pgBHAT was co-transfected with 
K082 viral DNA on Vero cells using LipofectAmine (Invitrogen Corporation, Carslbad, CA). 
Single recombinant virus plaques formed on Vero cells were purified three times by limiting 
dilution130. On each round of plaque purification, DNA from single plaque isolates in 96-well 
were screened by Southern hybridization with a gB probe that hybridized to the gB coding 
sequence. The positive plaques were then subjected to the next round plaque purification. The 
viral DNA was extracted from positive plaques after the third round isolation and subjected to 
polymerase chain reaction (PCR) using primers that flank the locus of the HAT insertion 
(forward 5’-CTCTTGGGGTTGACGCTGGGGG-3’, reverse 5’-GTTTGCATCGGTGTTC 
TCCGCC-3’). The PCR product was further subjected to DNA sequencing analysis to verify 
the incorporation HAT coding sequence in KgBHAT genome. 
2.4 SOUTHERN BLOT HYBRIDIZATION 
Southern blot analysis was performed to confirm that KgBHAT genome carries the HAT 
coding sequence. Viral DNA of KgBHAT and control virus K082 were digested with BamHI 
or HpaI, separated on an agarose gel, and transferred to a nitrocellulose membrane for 
analysis. A biotin-labeled gB probe was synthesized from a 1.3kb SphI and SalI digested 
pTZ18UgBpK- fragment using North2South biotin random prime kit (Pierce Biotechnology, 
Rockford, IL). The hybridization and detection procedures were followed according to 
North2South chemiluminescent nucleic acid hybridization and detection kit (Pierce 
Biotechnology). 
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2.5 WESTERN BLOT HYBRIDIZATION 
Western blot analysis was performed to verify the presence of HAT peptide on HSV-1 gB 
molecule. Vero cells were infected with KgBHAT or control virus KgBpK- respectively. 48 
hour after infection, cells were harvested, pelleted, washed with PBS, and lysed in RIPA 
buffer (150 mM NaCl, 10 mM Tris, 0.1% SDS, 1% Triton X-100, 1% Deoxycholate, 5 mM 
EDTA, 1 mM phenylmethylsulfonyl fluoride, and 10 mM benzamidine). After clarification 
by centrifugation, an appropriate amount of supernatant was mixed with 4X NuPAGE LDS 
Sample Buffer (Invitrogen, Carlsbad, CA) and heated at 70oC for 10 minutes. Each protein 
sample was loaded into duplicated wells on NuPAGE Novex Tris-Acetate gel (Invitrogen, 
Carlsbad, CA) and electrophoresed. The gel proteins were then transferred onto Immobilon-P 
PVDF membrane (Millipore, Billerica, MA). The membrane was cut into halves with each 
half containing proteins from both KgBHAT and KgBpK- samples. The membranes were 
probed separately either with a rabbit polyclonal antibody (Clontech, Palo Alto, CA) against 
HAT peptide, or with a HSV gB monoclonal antibody (Virusys, Sykesville, MD) overnight at 
4oC in PBS containing 2% dry milk. The membranes were then washed with PBS containing 
0.05% tween-20, incubated with either anti-rabbit or anti-mouse horseradish peroxidase 
conjugated antibodies (Sigma, St. Louis, MO) in 2%Milk/PBS for 1 h at 25oC.  After 
additional washes, the membranes were juxtaposed together and the signals were developed 
into one X-film according to the standard protocol using the Amersham ECL kit (Amersham 
Pharmacia Biotech, Piscataway, NJ). 
2.6 VIRUS ADSORPTION ASSAY 
Monolayers of confluent Vero cells in 6-well plates were incubated at 4oC with 250 
pfu/well of KOS, KgBpK-, or KgBHAT viruses suspended in 1ml/well serum medium 
(DMEM containing 10% FBS) for 10 to 110 min, after which the unbound viruses were 
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removed and the cell monolayer was washed three times with cold serum medium. The cell 
monolayer was subsequently overlaid with 2 ml serum medium containing 0.5% 
methylcellulose, shifted to 37oC, and incubated for 2 days to allow plaques to form. In control 
wells, the cells were incubated with the viruses for 2 h at 4oC, the plates shifted to 37oC for 
additional 1 h incubation, and the previous medium replaced with 2 ml methylcellulose 
medium. The plaques formed in each well were counted and normalized to control wells. The 
increase in normalized plaque number with the increase of adsorption time was taken as a 
measure of mutant virus adsorption rate. 
2.7 VIRUS PNENETRATION ASSAY 
The penetration rate of the gB mutants was assayed by determining the rate at which 
penetrated virus became resistant to inactivation by treatment of infected monolayer with 
low-pH glycine buffer. Confluent Vero cells in 6-well plates were incubated with 250 
pfu/well of KOS, KgBpK-, or KgBHAT in 1 ml/well serum medium for 2 h at 4oC. Following 
adsorption, the cells were rinsed three times, overlaid with serum medium, and shifted to 
37oC to allow virus penetration. At selected times after shifting, cells will be treated with 1 
ml/well 0.1 M glycine (pH 3.0) for 1 min to inactivate virus that had not penetrated the cells. 
The control monolayer was treated with 1 ml PBS for 1 minute. The cells will be washed 3 
times with complete medium, overlaid with methylcellulose medium, and incubated in 37oC 
for 2 days. Plaques were visualized and counted as described above. 
2.8 VIRUS PROPAGATION 
QOZHG virus was propagated in 7B cells at 37oC in roller bottles containing 100ml 
D-MEM supplemented with 10% FBS, while KgBHAT virus and its counterpart KgBpK- 
virus were propagated in Vero cells using UltraMDCK serum free medium (Cambrex 
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Bioscience Inc., Baltimore, MD) by the same procedure. Upon cell confluence in a 150 cm2 
vented cap polystyrene tissue culture flask (Becton Dickinson, San Diego, CA), the original 
cell culture medium was removed, and 2 ml cell culture medium (10% FBS in DMEM for 
QOZHG, UltraMDCK for KgBHAT) containing 2x106 pfu (plaque forming unit) QOZHG or 
KgBHAT viruses was added into the flask. This resulted in a multiplicity of infection (MOI) 
of 0.1 pfu/cell. After 1 hour infection at 37oC, 18 ml of fresh cell culture medium (10% FBS 
in DMEM for QOZHG, UltraMDCK for KgBHAT) was added over the infected cell 
monolayer and incubated at 37oC for 3 days for the virus replication. 
2.9 VIRUS HARVEST AND PROCESSING 
The infected cells typically detach from the surface at about 72h post-infection. At that 
time, the culture was harvested and mixed with 2 M NaCl in PBS (pH 6.5) to the final salt 
concentration of 0.5 M in order to release cell-associated viruses. Cell debris was removed by 
centrifugation at 2,000g for 10 minutes. The virus supernatant was further clarified by 
filtering through a 1.2μm Acrodisc syringe filter (Pall Life Science). The clarified supernatant, 
designated as crude supernatant, was used as loading sample for the subsequent IMAC step. 
Alternatively, the crude supernatant was centrifuged at 20,000g for 1 h to pellet the viruses. 
The virus pellet was resuspended in PBS, 0.5 M NaCl, pH6.5. The virus suspension, 
designated as partially purified virus preparation or pellet suspension, was also used as a 
loading sample for the IMAC. 
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2.10 IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY 
Chromatography was performed with a 1 ml HiTrap IDA metal-chelating column. An 
LKB P-1 pump was used to load samples and buffers (both the column and the pump were 
from GE Healthcare, Piscataway, NJ). The column was washed with 5 column volumes (CV) 
of distilled water and then loaded with 5 CV of selected metal CuSO4, ZnCl2, NiSO4, and 
CoCl2 in water. The column was subsequently washed with 7 CV of distilled water followed 
with 7 CV of PBS, 0.5 M NaCl, pH4.0 buffer. This step was used to remove any 
nonspecifically bound metal ions. The column was then equilibrated with 7 CV of 
equilibrium buffer (PBS, 0.5M NaCl, pH6.5) or equilibrium buffer containing various 
concentrations of ascorbate or imidazole as noted for each experiment. Virus samples which 
were harvested and processed, as noted earlier, were directly loaded on the column with or 
without ascorbate or imidazole. After loading the sample, the column was washed with 4 CV 
of the equilibrium buffer. Bound viruses were eluted with 4 CV of a low pH buffer (PBS, 0.5 
M NaCl, pH5.5) or the same buffer containing various concentrations of ascorbate. 
Alternatively, the column was eluted with an imidazole containing buffer (PBS, 0.5M NaCl, 
140 mM imidazole, pH6.5). Finally, an EDTA containing buffer (PBS, 0.5 M NaCl, 50 mM 
EDTA, pH6.5) was used to strip the metal ions and any residual bound materials from the 
column. The loading virus suspension and all of the elution fractions were assayed for virus, 
total protein, and DNA concentrations.  
2.11 PLAQUE ASSAY 
The quantification of infectious viral particles was accomplished by a standard plaque 
assay. Serial dilutions of virus were added to 8 x105 Vero cells in a 1.7 ml Eppendorf tube and 
rocked on a Nutator rocker (Becton Dickinson, San Diego, CA) at 37°C. After a 1 h 
adsorption period, the cells were plated in six-well plates. After 12 h, the inoculum was 
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replaced with complete medium containing 0.8% (wt/vol) methylcellulose (Aldrich, 
Milwaukee, WI.) and incubated for an additional 2 days. The plates were then stained with 
1% (wt/vol) crystal violet (Aldrich, Milwaukee, WI.) in 50% methanol–50% H2O (vol/vol), 
and the numbers of plaques were counted. Titers were calculated as PFU per milliliter of 
virus suspension. 
2.12 PROTEIN AND DNA ASSAYS 
Total protein concentrations in loading samples and elution fractions were measured with 
a Bio-Rad (Hercules, CA) protein assay kit. Bovine serum albumin was used as the standard 
protein for calibration. A Picogreen double-stranded DNA quantitation kit (Molecular Probes, 
Inc., Eugene, OR) was used to measure the DNA concentrations in all of the samples, with 
lambda DNA used as a calibration control. All assays were performed in triplicate under the 
conditions specified by the manufacturers. 
2.13 TAQMAN REAL-TIME QUANTITATIVE PCR 
Primer and probe specific to HSV-1 ICP47 gene sequence were used for the 
quantification of viral genomes. Q-PCR assays were conducted in 50 μl PCR volume 
containing 2 μl of DNA samples or standards, 400 nM of each primer, 200 nM Probe, and 
1xTaqMan Universal PCR Master Mix (PE Applied Biosystems, Foster City, CA). Primer 
sequences for ICP47 (sense- CACGACATGCTTTTCCCGA, and 
antisense-TTCCCGCAGGAGGAACG) were designed using the Primer Express program 
(PE Applied Biosystem). The TaqMan probes for detection of ICP47 
(CGCCGGTCGCCTCGACGA) were labeled with fluorescent reporter dye 6-FAM at the 5’ 
end and the quencher dye TAMRA at the 3’ end (PE Applied Biosystem). All PCR reactions 
were set up in a MicroAmp Optical 96-well Reaction Plate (PE Applied Biosystem). 
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Amplification conditions were 2 min at 50°C and 10 min at 95°C for the first cycle, followed 
by 40 or 50 cycles of 95°C for 15 sec and 60°C for 1 min. Standard curves for viral genes 
ICP47 were generated using 10-fold serial dilutions of plasmids known to contain the 
respective target sequences. The emission data was collected in real-time from an ABI 
PRIME 7000 Sequence Detector and analyzed by Sequence Detection program. 
2.14 ELECTRON SPIN RESONANCE 
Samples for ESR measurement were prepared as followed. 10 l of 
5,5-dimethylpyrroline-N-oxide (DMPO, Aldrich, Milwaukee, WI) solution (1M in buffer A) 
was added in 90 l of one of the following samples: KgBHAT crude supernatant, KgBHAT 
pellet suspension in pH6.5 buffer (PBS, 0.5M NaCl, pH6.5), or the crude supernatant 
containing 20 mM ascorbate. The resultant mixture was added to 100 μl of IDA-Co2+ beads. 
The beads were obtained from a HiTrap IDA metal-chelating column charged with cobalt 
ions as described in the Immobilized Metal Affinity Chromatography section. 10 μl of the 
bead slurry was transferred into a capillary tube and subjected to ESR measurement. 
EPR spectra were recorded at room temperature using a Bruker Elexsys E580 
spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany) operating at 904 GHz with a 
100-kHz modulation frequency. A microwave power of 20 mW and modulation amplitude of 
1 G was employed. Spectra were simultaneously recorded on an IBM computer interfaced to 
the spectrometer. 
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3.0 DEVELOPMENT OF IMMOBILIZED COBALT AFFINITY 
CHROMATOGRAPHY FOR HSV-1 VECTOR PURIFICATION 
Herpes simplex virus type 1 (HSV-1) is a promising vector for gene therapy applications 
particularly to peripheral nerves, the natural site of virus latency. Many gene vectors require 
large particle numbers for even early phase clinical trials emphasizing the need for high yield, 
scalable manufacturing processes that result in virus preparation nearly free of cellular DNA 
and protein contaminants. HSV-1 is an enveloped virus that requires the development of 
gentle purification methods. Ideally, such methods should avoid centrifugation and may 
employ selective purification processes that rely on the recognition of unique envelope 
surface chemistry. Here we describe a novel method that fulfills these criteria. An 
immobilized metal affinity chromatography (IMAC) method is described for the selective 
purification of vectors engineered to display a high affinity binding peptide. Feasibility 
studies involving various transition metal ions (Cu2+, Zn2+, Ni2+, and Co2+) showed that 
cobalt had the most desirable features which include low interaction with either normal virus 
envelope or contaminating DNA and proteins. The introduction of a cobalt specific 
recognition element into the virus envelope may provide a suitable target for cobalt 
dependent purification. To test this possibility, a peptide with affinity for immobilized cobalt 
was engineered in-frame in the heparan sulfate (HS) binding domain of HSV-1 glycoprotein 
B (gB) known to be surface exposed on the virion particle and recombined into the viral 
genome. By optimizing IMAC loading conditions and reducing cobalt ion leakage, we 
recovered 78% tagged HSV-1 recombinant virus with greater than 96% reduction in 
contaminating proteins and DNA.  
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3.1 INTRODUCTION 
Human herpes simplex virus type 1 (HSV-1) is a neurotropic DNA virus that has been 
engineered for gene transfer applications including human gene therapy. HSV-1 based vectors 
exhibit the advantages of broad host cell range, large transgene packaging capacity, and 
potentially lifelong transgene expression in neurons using components of the natural virus 
latency promoter system131, 132. Recent reports describe extensive efforts to improve the 
quality of replication defective, genomic based, HSV-1 gene vectors, including reducing 
vector cytotoxicity, exploiting viral persistence in neurons for long term gene therapy, and 
targeting vector tropism by glycoprotein modification61-63, 127, 133. This class of HSV-1 vectors 
has been exploited for treatment of animal models of pain50, 134-137, peripheral neuropathy138, 
139, and cancer57, 77, 140-143. In addition, characterization of the optimum conditions for 
replication defective vector growth enabled the efficient production of clinically relevant 
quantities of this vector144-147. However, efficient, validated methods for purification of vector 
nearly free of contaminating protein and nucleic acid are in development, and are required for 
advancing HSV-1 based gene therapy for patient applications.  
Currently, HSV-1 vector preparations are harvested by clarifying the virus from cell 
debris using low speed centrifugation followed by a high speed centrifugation step to pellet 
the virus from soluble protein and DNA molecules148, 149. However, cell organelles, proteins, 
and DNA aggregates co-sediment along with the viral particles during the second 
centrifugation step. Removal of those impurities in the virus preparation conventionally relies 
on density gradient centrifugation149-152, which is both time and labor intensive, and is not 
easily amenable to scale up. Moreover, gradient centrifugation may not remove particular 
contaminants that have size and density properties very close to those of the viral particles.  
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Replacing the gradient centrifugation in HSV-1 vector purification with a more efficient and 
scaleable purification method such as column chromatography will provide more efficient 
and cost-effective vector purification.  
Column chromatography such as ion exchange or size exclusion has been used in 
purification of retrovirus69, 153, adenovirus and adeno-associated virus (AAV) 77gene therapy 
vectors as well as HSV vaccines79. Although these procedures can be effective, they may 
prove less efficient than ligand affinity chromatography. Immobilized metal affinity 
chromatography (IMAC) is a powerful and inexpensive ligand affinity purification method 
used in purification of a variety of proteins and peptides. IMAC utilizes the affinity 
interaction between the immobilized transition metal ions, such as Cu2+, Zn2+, Ni2+, or Co2+, 
and protein surface electron-donating groups, such as histidine, cysteine, and tryptophan 
residues. In comparison to affinity separation utilizing bio-molecules, such as antibodies or 
receptors, the chromatography substrate used in IMAC is more stable and inexpensive while 
providing the same high selectivity. Although IMAC was introduced two decades ago85, it has 
been mainly applicable to protein and peptide purification. Recently this technique was 
reported for purification of adenovirus75, adeno-associate virus94, and retrovirus95.  
In this chapter, we report the use of IMAC for purification of recombinant HSV-1 
preparations that have been clarified and concentrated by centrifugation or other methods 
such as filtration. In order to select the proper IMAC column, we first evaluated elution 
profiles for both HSV-1 vector and contaminants (protein and DNA) on iminodiacetate (IDA) 
chelating columns charged with different transition metals (Cu2+, Zn2+, Ni2+, and Co2+). 
Chromatographic analysis showed that neither the virus nor the contaminants bound 
IDA-Co2+, suggesting that this column could be useful for HSV-1 vector purification if the 
vector could be endowed with the ability to bind to immobilized cobalt. Accordingly, we 
constructed an HSV-1 recombinant with a cobalt affinity tag replacing the heparan sulfate 
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(HS) binding domain of virion envelope glycoprotein B (gB). The binding and elution 
properties of the recombinant virus on IDA-Co2+ columns confirmed that efficient 
purification was possible. This method may also prove to be broadly applicable to 
purification of gene transfer vectors derived from different virus backgrounds.    
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3.2 RESULTS 
3.2.1 Immobilized Metal Affinity Chromatography for Untagged HSV-1 
The binding selectivity of IMAC can be tailored through the choice of metal ions, buffer 
conditions or by surface modification of the target product (protein, cell, or virus). The most 
desirable scenario would be that IMAC, using one of the commonly employed transition 
metal ions (Cu2+, Zn2+, Ni2+, Co2+), could be used to substantially purify HSV-1 based vectors. 
Therefore, we first examined the feasibility of using those metal ion columns for the 
purification of untagged HSV-1.  
The HSV-1 based vector QOZHG126 was used to test the binding and elution properties 
of untagged HSV-1 in IMAC. QOZHG is a replication defective virus deleted for the 
essential IE genes and contains expression cassettes for both lacZ and green fluoresscent 
protein (GFP). The vector was grown on 7B cells that complement in trans the missing 
essential viral genes. QOZHG was harvested from virus-infected cells, clarified by low speed 
centrifugation and concentrated by high speed centrifugation (see chapter 2 Materials and 
Methods for details). An aliquot of virus was re-suspended in loading buffer (PBS, 0.5M 
NaCl, pH7.0) and introduced into IDA columns charged with different metal ions. The 
columns were washed with loading buffer to remove any non-specifically bound material, 
eluted with a pH step gradient, and finally stripped with an EDTA containing buffer (PBS, 
0.5M NaCl, 50mM EDTA, pH7.0). The eluent samples were collected and assayed for 
protein and DNA content as well as infectious viral particles. The IDA-Cu2+ column (Fig.1) 
captured most of the loaded untagged virus with only a very small percentage of virus present 
in the flow through (0.67%) and the pH 7.0 wash fraction (0.29%). Protein and DNA also 
efficiently bound Cu2+ and was only removed by stripping the column with EDTA. Only a 
small percentage of infectious viruses were recovered by this method, suggesting that 
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exposure to the copper column resulted in virus inactivation. The Zn2+ (Fig.2), Ni2+ (Fig.3), 
and Co2+ (Fig.4) columns displayed decreasing protein, DNA, and virus binding, respectively. 
The protein, DNA, and virus elution profiles from the each of these four columns did not 
provide a means of separating virus from contaminants. However of interest was the finding 
that the Co2+ column bound minimal amounts of protein, DNA, and virus; in certain fractions 
(pH5.5 and pH5.0); negligible amounts of contaminant proteins and DNA were eluted from 
the column, thus creating a low background region. These results suggested that immobilized 
cobalt affinity chromatography might be useful for separating virus from contaminants if the 
virus particles could be tagged with a cobalt specific ligand to enhance virus binding to cobalt 
under loading conditions and subsequently eluted in the low background region identified.  
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Figure 1. Elution Profiles of Virus, Total Protein and DNA on IDA-Cu2+ Column. 
QOZHG virus after centrifugation was re-suspended in 10 ml loading buffer (PBS/0.5 M NaCl/pH 7.0) 
and applied on the columns. After washing with 5 column volumes (CV) of loading buffer, the columns 
were eluted with a pH step gradient (PBS/0.5 M NaCl, pH 6.5, pH 6.0, pH 5.5, and pH 5.0) using 5 CV 
per step and 5 CV of an EDTA solution (50 mM EDTA/PBS/0.5 M NaCl/pH 7.0) at a flow rate of 0.5 
ml/min. The percentages of virus, protein, and DNA in wash and step gradient elution factions are 
added and the summations represented by bars at the right side of each plots. The total amount of 
virus, protein, and DNA loaded on each of the columns was 2.4x107 pfu, 1.2 mg and 15.8 µg 
respectively. 
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Figure 2. Elution Profiles of Virus, Total Protein and DNA on IDA-Zn2+ Column. 
QOZHG virus after centrifugation was re-suspended in 10 ml loading buffer (PBS/0.5 M NaCl/pH 7.0) 
and applied on the columns. After washing with 5 column volumes (CV) of loading buffer, the columns 
were eluted with a pH step gradient (PBS/0.5 M NaCl, pH 6.5, pH 6.0, pH 5.5, and pH 5.0) using 5 CV 
per step and 5 CV of an EDTA solution (50 mM EDTA/PBS/0.5 M NaCl/pH 7.0) at a flow rate of 0.5 
ml/min. The percentages of virus, protein, and DNA in wash and step gradient elution factions are 
added and the summations represented by bars at the right side of each plots. The total amount of 
virus, protein, and DNA loaded on each of the columns was 2.4x107 pfu, 1.2 mg and 15.8 µg 
respectively.  
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Figure 3. Elution Profiles of Virus, Total Protein and DNA on IDA-Ni2+ Column. 
QOZHG virus after centrifugation was re-suspended in 10 ml loading buffer (PBS/0.5 M NaCl/pH 7.0) 
and applied on the columns. After washing with 5 column volumes (CV) of loading buffer, the columns 
were eluted with a pH step gradient (PBS/0.5 M NaCl, pH 6.5, pH 6.0, pH 5.5, and pH 5.0) using 5 CV 
per step and 5 CV of an EDTA solution (50 mM EDTA/PBS/0.5 M NaCl/pH 7.0) at a flow rate of 0.5 
ml/min. The percentages of virus, protein, and DNA in wash and step gradient elution factions are 
added and the summations represented by bars at the right side of each plots. The total amount of 
virus, protein, and DNA loaded on each of the columns was 2.4x107 pfu, 1.2 mg and 15.8 µg 
respectively.  
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Figure 4. Elution Profiles of Virus, Total Protein and DNA on IDA-Co2+ Column. 
QOZHG virus after centrifugation was re-suspended in 10 ml loading buffer (PBS/0.5 M NaCl/pH 7.0) 
and applied on the columns. After washing with 5 column volumes (CV) of loading buffer, the columns 
were eluted with a pH step gradient (PBS/0.5 M NaCl, pH 6.5, pH 6.0, pH 5.5, and pH 5.0) using 5 CV 
per step and 5 CV of an EDTA solution (50 mM EDTA/PBS/0.5 M NaCl/pH 7.0) at a flow rate of 0.5 
ml/min. The percentages of virus, protein, and DNA in wash and step gradient elution factions are 
added and the summations represented by bars at the right side of each plots. The total amount of 
virus, protein, and DNA loaded on each of the columns was 2.4x107 pfu, 1.2 mg and 15.8 µg 
respectively.  
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3.2.2 Construction of Cobalt Affinity Peptide Tagged HSV-1 Virus: KgBHAT 
Based on the above elution profiles (Fig.1-4), we postulated that the fusion of a short 
cobalt binding peptide to an HSV-1 virion surface protein might endow the virus with 
sufficient affinity for immobilized cobalt. This enhanced binding under loading conditions 
could also direct its elution to the low background region of the elution profile identified in 
Fig.4. For the peptide to be effective it must be exposed on the virus envelope and accessible 
for binding to the immobilized cobalt. Moreover, the peptide-bearing virus should be 
minimally adversely affected in its ability to efficiently bind to the normal HSV-1 cell surface 
receptors and enter into the target host cells.   
A 19-mer polyhistidine affinity tag (HAT), KDHLIHNVHKEEHAHAHNK90, that 
naturally exists in the N-terminus of chicken lactate dehydrogenase, has high affinity to 
cobalt ions and can be eluted in conditions milder than those for the His6 tag. Therefore, we 
selected HAT as a cobalt affinity peptide for incorporation into the HSV-1 virion. A 
replication competent HSV-1 viral recombinant carrying the HAT peptide in the HS binding 
site of glycoprotein B was constructed to evaluate the binding and elution properties of 
tagged HSV-1 on IDA-Co2+ column. A plasmid (pgBHAT) encoding HAT tagged gB (Fig.5B), 
was constructed with annealed oligonucleotides encoding the HAT peptide inserted into the 
deleted HS binding site in (Fig.5A), which encodes an HS binding deficient form of gB35. 
The HAT tagged gB construct was recombined into the HSV-1 genome by marker rescue of a 
gB nonsense mutant virus K082 (Fig.5C)129. The recombinant viruses were selected on 
non-complementing Vero cells, which cannot support the replication of the K082 parental 
virus, which was deficient for the essential viral gene gB.   
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Figure 5. Construction of Recombinant HSV Virus Expressing HAT Tag in gB. 
The HAT coding oligonucleotides containing BglII sticky ends were introduced into the BamHI site of 
the (A) plasmid pTZ18UgBpK-, in which the sequence encoding the HS binding domain of gB was 
replaced by a BamHI site, to create the plasmid (B) pgBHAT. The pgBHAT plasmid was used to rescue 
the gB defective mutant virus (C) K082, to create the recombinant (D) KgBHAT. (Abbrevations: 
UL=long unique segment; US=short unique segment; TMD=transmembrane domain; HS=heparan 
sulfate).  
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Southern blot analysis was performed to confirm the presence of HAT coding sequence 
in the recombinant virus genome. Viral DNA from K082 and 2 recombinant isolates were 
extracted from virus infected cells, digested with BamHI and HpaI, subjected to 
electrophoresis, transferred to a Nytran membrane then hybridized with a biotin labeled gB 
probe (Fig.5C). The gB probe hybridized to two fragments (3.1 Kb and 5.1Kb) in the parental 
K082 virus genome (Fig.6, lane 1) because of the existence of the HpaI site in the gB locus129. 
This HpaI site incorporates the stop codon in the parental virus and is a marker for the null 
gB phenotype. The gB probe hybridized to a single 8.2 Kb fragment in the putative HAT 
bearing isolates KgBHAT (Fig.6, lanes 2 and 3), demonstrating that this region in K082 
genome has been replaced with the sequences from pgBHAT by homologous recombination, 
or that the isolates were revertants that had rescued the gB nonsense mutation during passage 
on complementing cell lines. To verify the insertion of the HAT sequence within the gB locus 
of the recombinant viruses, candidate recombinant viruses were subjected to PCR with two 
primers flanking the locus of HAT insertion. The ~250bp PCR products were analyzed by 
DNA sequencing and the results verified that the HAT encoding sequences were inserted in 
those recombinant viral genomes in-frame in the proper orientation. 
To verify the expression of the HAT epitope, proteins were extracted from control virus 
KgBpK- and KgBHAT virus infected Vero cells and subjected to Western blot analysis using 
an anti-gB monoclonal antibody or an anti-HAT polyclonal antibody for detection. As shown 
in Figure 7, the gB antibody detected the HS binding deficient form of gB in KgBpK- (Fig.7, 
lane 1) and the HAT tagged gB in KgBHAT (Fig.7, lane 2) infected Vero cell samples. The 
HAT tagged gB is 28 amino acid residues longer than its HS binding deficient counterpart, 
resulting in 3.3 kDa molecular weight difference. This size difference is readily seen in Fig.7, 
as the tagged gB migrated slightly slower on the NuPAGE tris-acetate gel. The HAT antibody 
detected a protein with a molecular weight equivalent to the tagged gB in KgBHAT infected  
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Figure 6. Southern Blot Analysis 
Two rescued virus isolates (lanes 2-3) were digested with BamHI and HpaI and probed with the 
sphI-SalI fragment (Fig.5 D) of BamHI-F compared to the parental K082 (lane 1) virus. 
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Figure 7. Western Blot Analysis Detection of HAT-Tagged gB. 
Protein lysates from Vero cells infected with KgBHAT (lanes 2 and 4) and the control virus KgBpK- 
(lanes 1 and 3) were separated using the NuPAGE system and transferred to a PVDF membrane. The 
membrane was then cut in half and each was probed separately either with a monoclonal antibody 
against HSV-1 gB (lanes 1 and 2) or with a polyclonal antibody against HAT peptide (lanes 3 and 4), 
followed by detection using HRP-conjugated anti-mouse or anti-rabbit antibody respectively.  
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Vero cell sample (Fig.7, lane 4), confirming that the HAT peptide was successfully 
incorporated into gB. As expected, no HAT epitope was detected in the untagged KgBpK- 
infected control sample (Fig.7, lane 3). These experiments verify the insertion of the HAT 
sequences within the HS binding region of gB and the expression of the HAT peptide during 
productive infection. 
3.2.3 Infectivity and Productivity of KgBHAT 
Glycoprotein B is believed to be involved in both the adsorption and penetration steps 
during HSV-1 infection. Replacement of the HS binding region with the cobalt affinity 
peptide HAT within this glycoprotein may alter its function and affect infectivity or 
productivity of the recombinant virus.  
The infectivity of KgBHAT was compared to that of KOS and KgBpK- by measuring the 
adsorption and penetration kinetics on Vero cells. The adsorption studies were done at 4oC to 
avoid the complication of viral entry. As shown in Fig.8A, the adsorption rate of the three 
types of HSV-1 viruses was essentially the same within the 2 h incubation period on Vero 
cells. The rate of virus entry into host cells was determined as the rate at which penetrated 
viruses become resistant to low-pH glycine buffer treatment, compared with the untreated 
virus control. The results presented in Fig.8B show that the KgBpK- displayed an 
approximately 20% reduction in penetration rate compared to wild type virus KOS, which is 
consistent with published results35; while the penetration rate of the tagged virus KgBHAT 
was slightly lower than the KgBpK-. The data indicated that although virus binding was not 
affected by the gBHAT construction, virus entry was less efficient than wild type virus but 
not substantially different from the gB mutant lacking the HS binding element. 
The productivity of KgBHAT on Vero cells was determined and compared with that of 
wild type virus KOS. Vero cells were infected with either KgBHAT or KOS at the same MOI 
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of 0.01 and incubated at 37oC for virus propagation. At different time point post infection, 
samples from culture supernatant were taken and the number of viral particles produced was 
measured by standard plaque assy. Fig.9 shows that KgBHAT has the same productivity as 
KOS on Vero cells, suggesting that the virus production is not affected by the insertion of 
HAT tag in gB.  
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Figure 8. Infectivity of KgBHAT Virus on Vero Cells 
The relative infectivity of KgBHAT compared to KOS and KgBpK- viruses was assessed by measuring 
the virus adsorption (A) and penetration (B) kinetics on Vero cells.  
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Figure 9. Productivity of KgBHAT Virus on Vero Cells 
Vero cells were infected with KOS or KgBHAT at MOI of 0.01, and incubated at 37oC for virus 
propagation. 
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3.2.4 Chromatography of KgBHAT on IDA-Co2+ 
The binding and elution properties of KgBHAT on IDA-Co2+ column were investigated 
using a virus stock harvested from KgBHAT infected Vero cell supernatant. The infections 
were carried out in serum-free media. After harvesting, the virus stock was processed with 
two centrifugation steps. The virus containing supernatant was clarified from cell debris at 
2,000g, and the viral particles were pelleted from the supernatant at 20,000g. The virus pellet 
was then resuspended in a loading buffer (PBS, 0.5M NaCl, pH7.0) and loaded on an 
IDA-Co2+ column. The same chromatography procedures were employed for the tagged virus 
as those for untagged virus in Fig.1-4. The results demonstrated that by tagging gB with the 
HAT peptide, the elution of the KgBHAT virus was directed into the pH 5.5 elution fraction 
(Fig.10), a region shown to have insignificant amounts of contaminating proteins and DNA 
(Fig.4). The amount of KgBHAT virus in the pH 7.0 wash step and in the pH 6.5 elution 
fraction was negligible, demonstrating that the tagged virus efficiently binds cobalt ions 
above pH 6.5. Small amounts of bound viruses were eluted at pH6.0 and there was a major 
elution peak at pH 5.5, suggesting that the pH 5.5 buffer was sufficient to elute the majority 
of the bound virus from the immobilized cobalt column. Although the elution of the tagged 
virus from the column was directed to the low background area (Fig. 10), the recovery of 
virus, as measured by the percentage of recovered infectivity, was relatively low 
(approximately 20%) for this experiment. 
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Figure 10. Elution Profile of the Tagged Virus KgBHAT on IDA-Co2+ Column. 
Approximately 4.0x107 pfu of clarified KgBHAT virus was re-suspended in 10 ml loading buffer 
(PBS/0.5 M NaCl/pH 7.0) and applied on IDA-Co2+ column. After washing with 5 column volumes (CV) 
of loading buffer, the column was eluted with a pH step gradient as shown in the figures using 5 CV per 
step and 5 CV of an EDTA solution (50 mM EDTA/PBS/0.5 M NaCl/pH 7.0). The flow rate of the was 
0.5 ml/min.  
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3.2.5 IMAC Parameter Optimization 
To be effective, the IMAC purification should provide high infectious HSV-1 yield and 
high binding capacity for the viral particles. The effect of several IMAC parameters on the 
recovery and capacity of HSV-1 viruses during purification was investigated. The loading pH, 
flow rate, and chromatography substrate were optimized to achieve the high yield and high 
binding capacity of the tagged HSV-1 viruses.  
The effect of altering the loading pH on infectious virus recovery was examined for a 
range of pHs (Fig.11). For these assays, the KgBHAT virus pellets were re-suspended in 
buffers at pH 7.0, 6.5, 6.0 or 5.5 and loaded on the IDA-Co2+ column. The column was 
washed with loading buffer and eluted at pH 5.5, after which each column was stripped with 
EDTA to remove any remaining virus. Fig.11 shows that the summation of the viable 
KgBHAT virus percentage from all fractions increased as loading pH was decreased, 
although initial virus binding to the column was also reduced as loading pH was reduced. 
Virus loaded at pH 7.0 showed the highest column binding as demonstrated by the negligible 
amount of virus found in the flow through. However, the strength of this binding appeared to 
inactivate the viruses on the column, resulting in low total virus recovery (Fig. 11A). 
Lowering the loading pH to 6.5 also allowed high affinity to the column as confirmed by the 
minimal amount of virus collected from the flow through fraction and resulted in increased 
virus recovery at the pH 5.5 elution step (Fig.11B). A reduction in loading pH to 6.0 resulted 
in reduced virus binding to the column and increased virus in the flow through fraction (Fig. 
11C). This reduction in virus binding resulted in reduced relative recovery in the pH 5.5 
elution fraction compared to the pH 6.5 loading. When the samples were loaded at pH 5.5, a 
condition at which most viruses do not bind, a vast majority of the loaded virus was collected  
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in the flow through with a small amount recovered from the pH 5.5 elution step thereby 
suggesting that at the lower pH, virus binding was inefficient and not suitable for purification 
(Fig. 11D). 
These results suggested that loading the virus at higher pH (7.0) results in an avid 
column binding and lower recovery at pH 5.5 elution, whereas loading at lower pH (6.0) 
weakened the binding of the virus to the column resulting in overall virus loss due to flow 
through. The optimal balance of binding and recovery was seen by loading at pH 6.5 which 
was deemed optimal for purification of a HAT tagged virus on an immobilized cobalt 
column. 
The effect of flow rate on the performance of IMAC was investigated while keeping the 
loading pH at pH6.5. KgBHAT pellet was suspended in the pH6.5 buffer (PBS, 0.5M NaCl) 
and loaded on the IDA-Co2+ at different flow rates. The column was washed with the pH6.5 
buffer, eluted with the pH 5.5 buffer (PBS, 0.5MNaCl) and finally stripped with the EDTA 
buffer (PBS, 0.5M NaCl, 50 mM EDTA, pH6.5) at the same flow rate as the loading. Fig.12 
shows that increasing the flow rate from 0.5 ml/min to 1.0 ml/min gave rise to increased 
infectious virus recovery in the pH5.5 elution: from 45% (0.5ml/min) to 60% (1.0 ml/min). 
However, further increasing the flow rate to 1.5 ml/min did not have beneficial effect on the 
recovery, but resulted in decreased binding capacity, as the percentage of infectious viruses in 
the flow through was increased. Further more, the summation of the viable KgBHAT 
percentage from all fractions increased as the flow rate was increased, indicating that the 
shorter the viruses stay on the column, the less virus inactivation would be. Overall, Fig.12 
suggested that 1.0 ml/min was a suitable flow rate for the IMAC purification. 
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Figure 11. Effect of Loading pH on the Recovery of KgBHAT Virus on IDA-Co2+ Column. 
Clarified KgBHAT virus (4.0x107 pfu) was re-suspended in 10 ml of different loading buffers [PBS/0.5 M NaCl, pH 7.0 (A), pH 6.5 (B), pH 6.0 (C), and pH 5.5 
(D)]. After virus loading (flow rate=0.5 ml/min), the column was washed with 5 CV of the same loading buffer. The column was eluted with 5 CV PBS/0.5 M 
NaCl/pH 5.5 buffer if loaded in pH 7.0, pH 6.5, or pH 6.0. The columns in all the experiments were finally stripped with 5 CV of 50 mM EDTA/PBS/0.5 M 
NaCl/pH 7.0.). The percentages of recovered virus in wash and step gradient elution factions were added and the summations represented by bars at the right 
side of each plot.  
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Figure 12. Effect of Flow Rate on the Chromatography of KgBHAT on IDA-Co2+ 
Column. 
Clarified KgBHAT virus (4.0x108 pfu) was re-suspended in 5 ml of loading buffers [PBS/0.5 M NaCl, pH 
6.5, and loaded on the IDA-Co2+ column at different flow rate (A), 0.5ml/min (B), 1.0 ml/min and (C),1.5 
ml/min. Keeping the flow rate the same as loading, the column was washed with 5 CV of the same 
loading buffer, eluted with 5 CV PBS/0.5 M NaCl/pH 5.5 buffer, and finally stripped with 5 CV of 50 mM 
EDTA/PBS/0.5 M NaCl/pH 7.0.). The percentages of recovered virus in wash and step gradient elution 
factions were added and the summations represented by bars at the right side of each plot.  
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Breakthrough experiments were conducted on columns packed with various commercial 
IMAC substrates to measure the dynamic binding capacity of KgBHAT at 1 ml/min flow rate. 
Three commercial substrates were investigated: IDA beads from GE healthcare, NTA beads 
from Qiagen, and Talon beads from BD science. These chromatographic substrates are all 
derived from 6% agarose gel but with different bead diameters and functionized with 
different chelating ligands. The physical properties of the substrates are illustrated in Table 2. 
These substrates were packed into 50 X 5 mm I.D. glass columns using a downward slurry 
technique in equilibrium buffer (PBS, 0.5 M NaCl, pH6.5) at a flow rate of 3 ml/min. During 
the breakthrough experiments, 20 ml of KgBHAT suspension (1.5*108pfu/ml) in loading 
buffer (PBS, 0.5 M NaCl, pH6.5) was continuously pumped through the columns packed 
with different beads at a flow rate of 1 ml/min. The effluent was collected into 1-ml fractions, 
and the virus titer in each fraction was determined by standard plaque assay. The ratio of 
virus titer in the breakthrough fractions to that in loading was calculated and plotted against 
the fraction number in the breakthrough curve. The dynamic capacity was defined as total 
bound viruses at 10% breakthrough. 
 
 
 
 
 
 
 
 
 61
  
Figure 13.  Breakthrough of KgBHAT on different IMAC substrates 
Virus concentration in loading: 1.5*108 pfu/ml 
 
Table 2. Characteristics of IMAC substrates investigated. 
Substrates Talon NTA IDA 
Ligand 
 
 
 
Bead size 
(distribution) 
90 μm 
(45-165 μm)  
90 μm 
(45-165 μm) 
34 μm 
Dynamic 
capacity 1.5*10
8 pfu/ml gel 3.0*108 pfu/ml gel 8.5*108 pfu/ml gel 
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As shown in Fig. 13, among the substrates investigated, the IDA beads provide the 
highest dynamic binding capacity (8.5*108 pfu/ml gel), and the NTA and talon beads showed 
decreased dynamic capacity: 3.0*108 and 1.5*108 respectively. Thus the IDA beads appeared 
to be the suitable substrate for the purification of the tagged HSV-1 vectors on immobilized 
cobalt affinity chromatography. 
Experiments were conducted to test whether there was cobalt leakage from the column 
because this could be an important consideration in the acceptance of this method for 
purification of vector for clinical purposes. Atomic absorption analysis indicated that 4-5 
parts per million (ppm) of cobalt was present in the eluted samples. To address the problem of 
residual cobalt, an IDA column which is not charged with any metal ion was placed 
downstream of the immobilized cobalt column. The aim was to capture any cobalt ions that 
may leak from the purification column. This simple modification to the protocol indeed 
reduced the cobalt contamination in the final viral product to undetectable levels as measured 
by atomic absorption. In addition, we hypothesized that residual cobalt associated with 
purified virus could reduce infectivity. A second uncharged column should remove cobalt 
from the virus stock and thereby potentially increase virus infectivity and yield. As expected, 
the addition of an uncharged IDA column downstream of the cobalt charged column 
increased the total virus recovery up to 78% of the total loaded virus (Fig. 14) compared to 
around 60% observed with a single cobalt charged column (Fig. 12). The final protein 
concentration in the purified virus stock was 54 ng/ml, a reduction of more than 96.8 % from 
the loaded virus stock. The final DNA contaminant concentration was 3.5 ng/ml for a 
reduction of more than 96.7%.   
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Figure 14. Chromatography of KgBHAT on IDA-Co2+ Followed by a Downstream 
Uncharged IDA Column. 
Clarified KgBHAT virus (4.0x107 pfu) was re-suspended in 10 ml of loading buffer (PBS/0.5M 
NaCl/pH6.5). After loading (flow rate=1 ml/min.), the column was washed with 5 CV loading buffer. The 
column was subsequently eluted with 5 CV PBS/0.5M NaCl/pH5.5 buffer, and finally stripped with 5 CV 
50mM EDTA/PBS/0.5M NaCl/pH7.0 buffer.  
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3.3 DISCUSSION 
HSV-1 vectors provide a promising platform gene delivery technology especially for 
applications involving gene delivery to sensory nerves, the natural site of virus latency. Near 
term clinical applications include the treatment of certain solid tumors and sensory nerve 
conditions such as chronic pain and peripheral nerve degeneration. For patient applications, a 
scaleable and efficient purification process is an essential step in providing clinical grade 
HSV-1 vectors for early phase human trials to assess vector safety and eventual efficacy. The 
objective of this chapter was to test the feasibility of utilizing IMAC column purification and 
surface glycoprotein tagged virus to replace the current methods for purification of 
recombinant HSV-1 virus vectors.   
Initial experiments were aimed at determining whether one of the commonly used 
immobilized metal ion columns was able to separate untagged HSV-1 virus from protein and 
DNA contaminants. The binding of untagged HSV-1 to transition metal ions infers the 
existence of metal ion binding sites on the native virion surface. The outermost layer of the 
HSV-1 virion is a lipid membrane envelope from which at least 10 HSV-encoded 
glycoproteins (gB-gE, gG-gJ, gL, and gM) project beyond the lipid bilayer34, 154. Every 
glycoprotein contains a variable number of histidine residues and since only a single histidine 
is required for binding to IDA-Cu2+ 83, it is likely that some of these residues are exposed on 
the surface of the viral glycoprotein moiety producing strong binding between the HSV-1 
virion and the IDA-Cu2+ column. This interaction was so strong that untagged virus was 
resistant to elution even at low pH. There are also several polyhistidine clusters present in the 
amino acid sequences of some HSV-1 glycoproteins that may account for binding to Ni2+ and 
Zn2+. 
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The affinity of protein and DNA contaminants to each of the above immobilized metal 
ions followed the same trend as the untagged HSV-1 virus (Fig.1-4). No purification of 
untagged HSV-1 was achieved by solely selecting one of the above immobilized metal ion 
columns. However, the selectivity of IMAC can be tailored by surface modification of one or 
more of the viral glycoproteins.  Since the majority of virus or contaminants did not bind to 
the immobilized cobalt ion (Fig.4), augmentation of the affinity of HSV-1 virus to the cobalt 
ion could enhance binding and direct the elution of the virus into a fraction low in non-viral 
contaminants. We tested this possibility through engineering a cobalt affinity peptide into a 
virus surface glycoprotein.  
In order to construct an effective tagged HSV-1 recombinant, the peptide tag and the 
locus of tag insertion should be appropriately selected so that the tag must be accessible and 
bind to the cobalt ion. Moreover, the tag insertion must have minimal impairment of virus 
infectivity. It has been established that HAT is an efficient tag for cobalt ions90. Glycoprotein 
B was selected as the target for tag insertion because gB has the longest amino acid 
ectodomain among the HSV-1 glycoproteins155, and because the clustering of gB spikes in 
protrusions of the virion envelope156 implies that regions of gB are surface exposed and thus 
accessible for binding to the immobilized cobalt on the column. It is well known that gB 
participates in mediating adsorption of HSV-1 virion to susceptible cells by binding to the 
herapan sulfate (HS) moieties of cell surface proteins35, 37, 157, and subsequently in 
contributing to virus penetration into cell through envelope-membrane fusion158, 159. The HS 
binding domain (amino acids 68-76 KPKKNKKPK) of gB was selected to be replaced by the 
HAT peptide for the following reasons. First, the existence of an HS binding domain and the 
presence of a neutralizing epitope localized to this region of the molecule suggest that this 
domain of gB is exposed on the virion surface and can be easily recognized by one of its 
natural receptors (HS)35. Thus replacement of the HS-binding domain with the HAT tag may 
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also be available for binding cobalt. Second, most of the HS binding function of HSV-1 is 
contributed by gC while only minor HS binding activity is ascribed to gB35. Deletion of the 
HS binding domain results in a 20% reduction in virus infectivity on Vero cells. Third, it has 
been predicted by neural network computational analysis that insertional mutagenesis of the 
secondary loop structure region of gB protein can minimize the outcome of a miss-folded 
mutant, with the HS domain of gB predicted to be in a loop conformation160. The rationale for 
placement of the HAT tag into gB was supported by the experimental findings using the 
recombinant virus. The productivity of the tagged virus on Vero cells was not negatively 
affected by the insertion of the HAT tag in gB. The tagged virus was bound to the 
immobilized cobalt column and the elution profiles indicated that the virus particles could be 
directed into a fraction nearly devoid of contaminants.  
The effect of replacement of HS binding domain with HAT peptide on virus infectivity 
was assessed. It was found that, compared with wild type virus, virus mutant with HS binding 
deficient form of gB showed 20% reduction in binding capacity on mouse L cells after 5 
hours incubation 35. High amounts of radioactive virus particles (over 1000 viruses/cell) were 
used in the adsorption assay in order to see the capacity difference of different virus mutants. 
In HSV-1 vector gene transfer applications, the multiplicity of infection applied is normally 
far from the virus binding capacity on target cells. More interesting to us is the rate of the 
virus adsorption. In this work, we found that, when low MOI (250pfu/106 cells) was used, 
KgBpK- or KgBHAT shows essentially the same adsorption rate as KOS on Vero cells 
(Fig.7A). The rate of penetration of KgBHAT on Vero cells was found slightly lower than its 
KgBpK- counterpart (Fig.7B). This minimal loss in tagged virus infectivity is compensated 
by gains in vector purity and more economical manufacturing. 
The recovery of viable virus from IMAC varies with different chromatography 
conditions and different metal ions used. It appeared that the stronger the virus binding to 
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metal ions or the longer contacting time of the virus with metal ions, the greater the extent of 
metal ion induced virus inactivation. For example, the immobilized copper ion appeared to 
strongly bind to untagged virus, thus the recovery of infectious virus from copper IMAC was 
significantly lower than for the other columns tested. Sagripanti et al found that HSV-1 can 
be inactivated in Cu2+ solution by free radicals generated from a series of Cu2+ catalyzed 
redox reactions, referred to as Fenton reactions161. Similar free radicals could be generated 
during IMAC purification and cause virus inactivation, which could account for the 
inactivation of untagged virus in IDA-Cu2+ column (Fig.1) and the tagged virus in IDA-Co2+ 
column (The free radical mediated virus inactivation will be systematically investigated in the 
next chapter). As shown in Fig. 11 and Fig. 12 decreasing the binding strength and reducing 
the resident time of the virus on the column would minimize virus inactivation. 
The effect of chromatographic substrates on the binding capacity of the tagged HSV-1 
virus was also investigated. Among three commercial available substrates studied, the IDA 
beads from GE healthcare provided the highest virus binding capacity. The chelating ligand 
in the IDA beads, iminodiacetate has three metal binding sites, while the ligands in the talon 
and NTA beads have four metal binding sites. Consequently, cobalt ions immobilized by the 
IDA beads have one more orbital for the virus binding, which resulted in higher virus binding 
affinity. In addition, the IDA beads have a smaller diameter and higher total surface area than 
the NTA and talon beads. Since the virus could not penetrate inside the beads due to its large 
diameter, only surface binding occurs during IMAC. The higher binding capacity in the IDA 
beads could partly be due to the higher total surface area on the IDA beads.  
 Elution from a single cobalt charged column resulted in loss of infectious virus and the 
concomitant presence of leeched cobalt in the eluate. Thus, cobalt bound to gB on the viral 
envelope may interfere with essential function of gB similar to the inhibition seen by adding  
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Co2+ directly to an aliquot of KgBHAT stock (data not shown). We found that Co2+ leakage 
was substantially mitigated simply by connecting a metal-free IDA column downstream to 
capture the free and/or virus bound Co2+.  
By loading the virus in pH 6.5 at 1ml/min, and using the second uncharged column 
downstream (Fig.14), the recovery of tagged HSV-1 virus from IDA-Co2+ was increased to 
approximately 80%, while protein and DNA contamination was reduced by more than 96.5% 
for protein and DNA, that is 54 ng/ml and 3.5 ng/ml respectively. Together, these results 
suggest that introduction of a HAT tag into HSV-1 gB enabled the rapid purification of the 
recombinant virus using immobilized cobalt columns.   
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4.0 INACTIVATION OF HSV-1 VECTOR ON IMMOBILIZED COBALT AFFINITY 
CHROMATOGRAPHY BY HYDROXYL FREE RADICALS  
Metal catalyzed oxidation (MCO), which typically involves oxygen free radical 
generation, is an important pathway that leads to the deterioration of many biological 
molecules in solution. The occurrence of MCO in immobilized metal affinity 
chromatography (IMAC) systems and its potential for inactivating biological products has not 
been well recognized. In this chapter, we report the inactivation of HSV-1 vector on 
immobilized cobalt affinity chromatography. We observed that purification of KgBHAT on 
IDA-Co2+ columns using crude supernatant as starting material resulted in signification loss 
in virus infectivity (<5% recovery). Electron spin resonance (ESR) revealed that the virus 
inactivation was caused by hydroxyl free radicals generated from the interactions between 
cellular impurities and the metal ions on the column. Inclusion of 20 mM ascorbate, a free 
radical scavenger, in the chromatography mobile phase effectively scavenged the hydroxyl 
radicals. Alternatively, the hydroxyl radical formation could be effectively prohibited by 
inclusion in the chromatographic mobile phase of 20 mM imidazole, a competitive agent 
usually used to elute bound material from IMAC columns. In both cases, the infectivity 
recovery was dramatically augmented to 70%. This finding is the first demonstration of 
oxygen free radical mediated biological inactivation in an actual IMAC purification and an 
effective method to prevent it.  
4.1 INTRODUCTION 
Transition metal ions form coordination complexes with a variety of cofactors and 
proteins in cells where they carry out crucial regulatory and catalytic roles, particularly in 
electron transfer in many important redox reactions 107, 162. However, this essential ability of 
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metal ions to transfer electrons can make them toxic to cells when present in excess. The 
toxic effects are partly due to their capability of generating oxygen free radicals such as 
superoxide or hydroxyl radicals 103-105. These highly reactive free radicals can cause 
irreversible oxidative damages to proteins 113, 114, nucleic acids 115, 116, and lipids 117, 118, 
resulting in deleterious biological consequences such as aging 118, carcinogenesis 116 and 
other disease states 119, 120. Metal catalyzed oxidation (MCO) is also an important pathway 
that leads to the inactivation, modification, or degradation of biological products during 
bioprocessing, transportation, and storage in vitro 121. The nonenzymatic MCO pathway 
typically starts with the binding and reduction of molecular oxygen to hydrogen peroxide on 
the reduced state of chelated metal ions (e.g. Fe2+, Cu+, or Co2+) in the presence of an 
appropriate reducing agent, with or without a superoxide intermediate 103, 121. The resultant 
peroxide reacts with the reduced metal ions to generate highly reactive hydroxyl radicals that 
rapidly oxidize essentially any biological molecules they encounter 163. 
During IMAC purification, immobilized transition metal ions contact a wide variety of 
compounds in the mobile phase, which may include dissolved oxygen and reducing agents 
from cell culture. Thus, there are possibilities that the metal ions could trigger free radical 
generation and cause damage to the biological product which is being purified by IMAC. 
Inactivation of lactate dehydogenase has been reported when exogenous hydrogen peroxide 
or reducing agents such as ascorbate, glutathione or cysteine were intentionally introduced 
into IDA-Cu2+ column to create the MCO conditions 122, 164. However, no inactivation of 
lactate dehydrogenase was observed during the actual IMAC purification in which no 
exogenous reducing agent was deliberately introduced 122, 164. Indeed, free radical mediated 
inactivation of biological products in an actual IMAC purification has not yet been reported.  
In this chapter, we demonstrate significant infectivity loss of HSV-1 vectors during 
chromatography on an IDA-Co2+ column, when crude virus supernatant was used as starting 
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material. Electron spin resonance (ESR) revealed that the virus inactivation was caused by 
hydroxyl free radicals generated from reaction between soluble impurities from cell culture 
and the immobilized cobalt ions. Inclusion of 20 mM ascorbate or imidazole in the 
chromatography mobile phase effectively prohibited hydroxyl radical generation and 
dramatically reduced virus inactivation. The results are the first demonstration of free radical 
mediated damage of biological product during an actual IMAC purification and we describe 
methods to overcome this problem using free radical scavengers.    
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4.2 RESULTS 
4.2.1 Inactivation of KgBHAT on IDA-Co2+ Column 
In Chapter 3, we developed an immobilized cobalt affinity chromatography for selective 
purification of HSV-1 vectors engineered to display a cobalt affinity tag (HAT) on viral 
envelope glycoprotein B (gB), referred to as KgBHAT. KgBHAT was first partially purified 
from cell debris and soluble protein/DNA impurities using two centrifugation steps. Then, 
this partially purified preparation was used as starting material for further purification on 
IDA-Co2+ column.  
To fully exploit the high specificity of the affinity between immobilized cobalt and the 
tagged HSV-1, it was desirable to assess the feasibility of IMAC purification of KgBHAT 
from a crude preparation. The second step centrifugation which was used to pellet the viruses 
from soluble impurities in Chapter 3 was omitted here. The crude KgBHAT supernatant, 
obtained after salt-releasing and clarification (see Chapter 2 Materials and Methods), was 
directly loaded on the IDA-Co2+ chromatography column and eluted as summarized in Table 
3. The loading volume was 2 ml, which contained the amount of viruses (5.1*108 pfu/ml) 
corresponding to a column dynamic capacity of 10% breakthrough for the flow rate of 1 
ml/min. This crude supernatant contained substantially higher amounts of soluble impurities 
than the partially purified sample used in our earlier work. The large amounts of impurities 
present in the crude sample did not lead to any complication, as most of protein and DNA 
impurities still did not bind to IDA-Co2+ and were removed in the flow through and washing 
fractions. However, only 4.9% of the loaded virus infectivity was found in pH 5.5 elution. 
This fraction constituted our purified virus and thus it indicated an effective virus recovery of 
4.9%. Table 3 also shows that total infectious viruses found in all output fractions was 
substantially lower (about 25%) than the number of loaded infectious particles. The output 
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fractions were distributed as follows: flow through (11.5%), washing (7.1%), pH 5.5 elution 
(4.9%), and the EDTA striping fractions (2%). The low amounts of infectious virus present in 
output suggested that the majority of bound viruses were inactivated during the 
chromatography. In addition, we found that using an uncharged chelating column 
downstream the IDA-Co2+ column did not have significant effect on the infectious virus 
recovery in this case. 
To further understand the virus inactivation, samples from each fraction were subjected 
to TaqMan real-time quantitative PCR (Q-PCR). Q-PCR with primer pair and probe 
specifically hybridized to HSV-1 gene ICP47 was used to amplify and quantify HSV-1 
genomes (both the infectious and non-infectious ones). The non-infectious genomes consist 
of naked viral DNA, non-enveloped HSV-1 capsids, and HSV-1 virions with physical or 
chemical damages 34. Therefore, if only the viral proteins were damaged, Q-PCR should be 
able to detect the inactivated viruses. As shown in Table 3, Q-PCR detected extremely low 
genome number in the output fractions. The amount of Q-PCR detectible genome number 
from all output fractions is only a very small percentage of the input. This result suggested 
that the inactivation of KgBHAT on IDA-Co2+ happened at the DNA level so that the 
damaged viral genomes were not able to serve as functional templates for Q-PCR 
amplification.   
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Table 3. Chromatography of KgBHAT crude supernatant on IDA-Co2+ column. 
 
 
0.1±0.02 0.086±0.03 (0.8%) 0.84±0.3 0.86±0.2 21.2±2.2 Genome number (109/ml) 
0.64±0.04 1.7±0.5 (4.9%) 3.5±1.0 7.4±1.7 68.8±5.3 Infectivity (107pfu/ml) 
3.8±1.3 11.7±5.8 (3.2%) 199.8±2.3 339.1±15.1 723.6±3.5 DNA (ng/ml) 
1.8±0.8 3.8±1.8 (5.0%) 45.9±4.9 36.8±2.9 153.0±9.1 Protein (μg/ml) 
EDTA Elution Wash Flow through Loading Fractions 
 
2 ml of clarified KgBHAT crude supernatant was loaded on the column. After loading, the column was washed with 4ml of buffer A (PBS, 0.5 M NaCl, pH6.5). 
The elution of the bound viruses and other materials was achieved by passing 4 ml buffer B (PBS, 0.5 M NaCl, pH 5.5). The column was then washed with 
an EDTA containing buffer C (PBS, 0.5 M NaCl, 50 mM EDTA, pH6.5) to release the metal ions and remove any remaining viruses or impurities on the 
column. Flow rate was 1ml/min. The data represents the average of three independent experiments.  
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4.2.2 Stability of KgBHAT on Suspension 
To determine what caused the low recovery, we assessed the stability of KgBHAT in the 
crude supernatant in room temperature. KgBHAT pellet resuspended in elution buffer (PBS, 
0.5 M NaCl, pH5.5) and fresh cell culture medium UltraMDCK was used as control. As 
shown in Table 4, the virus had no statistically significant decay in 3 hours, a time period 
longer than the chromatography runs. The stable feature of KgBHAT in various suspensions 
indicated that Co2+ complexes on the column might have played a key role in the virus 
inactivation during the chromatography.  
In our previous experiments, KgBHAT was pelleted from the crude supernatant by 
centrifugation (20,000Xg, 1hr). The virus pellet was then resuspended in a loading buffer 
(PBS, 0.5 M NaCl, pH6.5), which had the same salt and pH conditions as the crude 
supernatant. When the virus pellet suspension was loaded on the column, the infectious virus 
recovery was significantly improved to about 60% (Fig. 12). This suggested that the soluble 
impurities removed by high speed centrifugation were responsible for the virus inactivation 
on IDA-Co2+.  
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 Table 4. Stability of KgBHAT in different suspension conditions.  
 42±4 
42±3 
43±3 
46±6 
B
107 pfu/ml 
41±3 41±2 3 
42±3 46±4 2 
41±2 43±3 1 
42±2 47±4 0 
C 
107 pfu/ml 
A 
107 pfu/ml  
Incubation time hr 
 
Decay rate of KgBHAT in (A) freshly prepared crude supernatant, (B) low pH elution buffer (PBS, 0.5 
MNaCl, pH5.5), or (C) fresh UltraMDCK cell culture medium at 25oC was analyzed. The virus 
suspensions in B and C were prepared by suspending partially purified KgBHAT pellet in the elution 
buffer and UltraMDCK medium, respectively. Samples were removed over time and analyzed for the 
presence of infectious virus using standard plaque assay. The data represents the average of three 
independent experiments.  
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4.2.3 Effect of Ascorbate on KgBHAT Inactivation 
Chelated Co2+ ions are known to have the ability to activate dioxygen and catalyze 
oxygen free radical generation. Based on the stable feature of KgBHAT in suspension (Table. 
4) and the virus inactivation on IDA-Co2+ (Table. 3), we hypothesized that the infectivity loss 
might be due to oxidative free radicals generated on cobalt complexes on the column. If this 
were the case, presence of free radical scavengers in the mobile phase should prevent the loss 
of infectivity. The effect of ascorbate, a water-soluble free radical scavenger, on preventing 
virus inactivation on IDA-Co2+ was studied. The ascorbate was present in the mobile phase 
throughout chromatography including the loading, wash, and elution buffers. The pH and the 
NaCl concentration in the buffers were not changed by the addition of ascorbate. The virus 
inactivation was defined as: 
% Inactivation =  100*
)(
)(
WFL
SEWFL
+−
+++−
       
where L, F, W, E, and S represent amount of infectious viruses present in loaded sample (L), 
flow-through (F), wash (W), elution (E), and final EDTA stripping step (S),  respectively.  
The term L – (F + W) represents the viruses that remain bound after washing is complete. The 
numerator denotes the amount of inactivated viruses. 
As shown in Fig. 15, when crude KgBHAT supernatant was used as starting material, 
the percentage of viruses recovered in elution increased with the increase in ascorbate 
concentration in the mobile phase. At a concentration of 20 mM, ascorbate almost completely 
prevented virus inactivation.  
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Figure 15. Effect of ascorbate on the virus inactivation when crude KgBHAT 
supernatant was used as loading material. 
Ascorbate buffer (PBS, 0.5 M NaCl, 200 mM ascorbate, pH6.5 or pH5.5) was added to the load (crude 
KgBHAT supernatant, pH6.5), the wash buffer (buffer A, pH 6.5), and elution buffer (buffer B, pH5.5) to 
the final ascorbate concentrations as indicated in the figure. The virus recovery and inactivation rates 
from IMAC runs were plotted against the concentration of ascorbate present in chromatography mobile 
phase. Flow rate was 1 ml/min. Two milliliters crude supernatant containing 1*109 pfu viruses in were 
loaded. The data represents the average of three independent experiments. 
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Figure 16. Effect of ascorbate on the virus inactivation when partially purified KgBHAT 
suspension was used as loading material. 
Ascorbate buffer (PBS, 0.5 M NaCl, 200 mM ascorbate, pH6.5 or pH5.5) was added to the load 
(partially purified KgBHAT suspension, pH6.5), the wash buffer (buffer A, pH 6.5), and elution buffer 
(buffer B, pH 5.5) to the final ascorbate concentrations as indicated in the figure. The virus recovery 
and inactivation rates from IMAC runs were plotted against the concentration of ascorbate present in 
chromatography mobile phase. Flow rate was 1 ml/min. 1*109 pfu viruses in 4 ml loading buffer were 
loaded. The data represents the average of three independent experiments. 
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However, at low concentration of 1 mM, ascorbate promoted virus inactivation instead 
of preventing it. The effect of low ascorbate concentration was more prominent when, instead 
of a crude virus preparation, a virus preparation that was first partially purified from cell 
debris and soluble protein/DNA impurities was applied to the column (Fig. 16). Partial 
purification of the virus preparation was achieved by centrifugation (20,000Xg, 1hr) of the 
crude supernatant and suspending the virus pellet in the loading buffer (PBS, 0.5 M NaCl, 
pH6.5), which had the same salt concentration and pH as the crude supernatant. As shown in 
Fig. 16, the presence of 1 mM ascorbate in partially purified suspension resulted in a 78% 
loss of infectivity as compared to 35% without ascorbate. Furthermote, comparison of Fig.15 
and 16 at zero concentration of ascorbate reveals that the removal of soluble impurities leads 
to a much lower inactivation rate.  
These experiments established that 20 mM ascorbate in mobile phase was able to 
effectively protect KgBHAT viruses from inactivation during the purification of crude 
supernatant on IDA-Co2+. Fig. 17 demonstrated the distribution of protein, DNA, and 
infectious viruses found in flow through, wash, elution, and EDTA fractions. The infectious 
virus recovered in elution was significantly increased from 4.9% in the absence of ascorbate 
(Table 3) to 72% in the presence of 20mM ascorbate in loading, wash, and elution buffers 
(Fig. 17). In contrast, the ascorbate had no effect on the elution profiles of protein and DNA 
impurities as most of the protein and DNA impurities were released in the flow through and 
wash steps, with less than 5% distributed in elution (Fig.17).  
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Figure 17. Inclusion of 20 mM ascorbate in mobile phase protected KgBHAT from 
inactivation. 
2 ml KgBHAT crude supernatant (5.1*109 pfu/ml) containing 20 mM ascorbate was loaded on an 
IDA-Co2+ column. After loading, the column was washed with 4 ml pH 6.5 buffer (PBS, 0.5M NaCl, 
pH6.5) containing 20 mM ascorbate. The bound viruses were eluted with 4 ml pH5.5 buffer (PBS, 0.5M 
NaCl, pH5.5) containing 20 mM ascorbate. Finally, 4 ml EDTA buffer (PBS, 0.5M NaCl, 50mM EDTA, 
pH6.5) was used to strip the column. Flow rate was 1ml/min. The distribution of virus, protein, and DNA 
in flow-through, wash, elution, and EDTA strip fractions are shown in the Figure. The data represents 
the average of three independent experiments. 
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Figure 18. Effect of ascorbate presence only in loading and wash (A) or only in wash 
and elution (B) on the recovery of KgBHAT. 
(A) 2ml KgBHAT crude supernatant (5.1*109 pfu/ml) containing 20 mM ascorbate was loaded on an 
IDA-Co2+ column. After loading, the column was washed with 4 ml pH6.5 buffer (PBS, 0.5M NaCl, 
pH6.5) containing 20 mM ascorbate. The column was eluted with pH 5.5 buffer (PBS, 0.5M NaCl, 
pH5.5) without ascorbte. (B) 2ml KgBHAT crude supernatant (5.1*109 pfu/ml) without ascorbate was 
loaded on an IDA-Co2+ column. After loading, the column was washed with 4 ml of the same pH6.5 
buffer containing 20 mM ascorbate. The column was eluted with the pH5.5 buffer containing 20mM 
ascorbte. Flow rate was 1ml/min. The data represents the average of three independent experiments. 
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Finally, we found that ascorbate had to be present in the loading suspension of the virus 
preparation to impart significant protection. As shown in Fig. 18, incorporation of 20 mM 
ascorbate in the washing and elution buffers increased the infectious virus recovery to 20% 
(Fig.18B); whereas adding the same amount of ascorbate in the loading and washing 
improved the recovery to 60% (Fig. 18A). As noted earlier, the infectious virus recovered in 
elution was 72% in the presence of 20mM ascorbate in loading, wash, and elution buffers 
(Fig. 17). Thus, virus inactivation occurs to a large extent during the loading of virus 
preparations on the chromatography column.   
4.2.4 Effect of Imidazole on KgBHAT Inactivation 
In practice, during IMAC purification, the retained product is usually eluted from the 
column with a buffer gradient either with decreasing pH or increasing concentration of 
imidazole. The imidazole competes with proteins for the binding to the chelated metal ion 
while the proton competes with the immobilized metal for the protein. 
It is of interest to examine if there is any improvement on the virus recovery by eluting 
the column with imidazole containing buffers. In Fig.19, same amount of KgBHAT crude 
supernatant was loaded on the IDA-Co2+ column as in Table 3. After loading, the column was 
eluted instead with an imidazole step gradient: 20mM imidazole (PBS, 0.5M NaCl, pH6.5) 
followed by 140mM imidazole (PBS, 0.5M NaCl, pH6.5). As shown in Fig.19, this imidazole 
elution strategy gave rise to a similar distribution of infectious viruses in the elution fractions 
as in Table 3: 10% in 20mM imidazole, 5% in 140mM imidazole, and 1.5% in the EDTA 
fraction. There was no improvement on virus infectivity recovery in any of the elution 
fractions. 
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Figure 19. Chromatography of KgBHAT crude supernatant on IDA-Co2+ column: 
eluting with imidazole gradient 
2 ml of clarified KgBHAT crude supernatant (5.3*109 pfu/ml) was loaded on the column. After loading, 
the column was eluted with 4ml of 20mM imidazole buffer (PBS-0.5 M NaCl, pH6.5), followed by 4ml of 
140mM imidazole buffer (PBS-0.5M NaCl, pH6.5). Finally, the column was passed through with an 
EDTA containing buffer (PBS-0.5 M NaCl, 50 mM EDTA, pH6.5) to release the metal ions and remove 
any remaining viruses or impurities on the column. Flow rate was 1ml/min. The data represents the 
average of three independent experiments.  
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Interestingly enough, if imidazole was also added in the loading material as well as in 
the elution, substantially higher virus infectivity recovery would be obtained. As shown in 
Fig. 20, keeping the rest IMAC protocol the same as in Fig.19, incorporation of 20mM 
imidazole in the loading led to significantly improved infectivity recovery in the 140M 
imidazole elution fraction. Fig.20 also shows that the majority of protein and DNA impurities 
did not bind to IDA-Co2+ as expected and were removed in the flow through and wash 
fractions. Only less than 5% of the total protein or DNA impurities were released in the 
140mM imidazole elution fractions. Fig. 20 demonstrates the effective purification of the 
tagged HSV-1 on IDA-Co2+ if using appropriate chromatographic procedure. 
We also found that imidazole does not have to be present in the elution to achieve the 
high recovery. As shown in Fig.21, when 20mM imidazole was included in the loading and 
the subsequent wash step, high infectious virus recovery (58%) was obtained by eluting the 
column with a pH5.5 buffer (PBS, 0.5 M NaCl, pH5.5). This high recovery in Fig. 21, in 
comparison with the low recovery in Fig. 20 where imidazole was present in wash and 
elution but not in loading, suggests that imidazole has to be present in the loading virus 
suspension to impact significant protection on the viruses. 
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Figure 20. Inclusion of 20 mM imidazole in mobile phase protected KgBHAT from 
inactivation. 
Two milliliters KgBHAT crude supernatant (5.3*109 pfu/ml) containing 20 mM imidazole was loaded on 
an IDA-Co2+ column. After loading, the column was eluted with 4ml of 20mM imidazole buffer (PBS-0.5 
M NaCl, pH6.5), followed by 4ml of 140mM imidazole buffer (PBS-0.5M NaCl, pH6.5). Finally, the 
column was passed through with an EDTA containing buffer (PBS-0.5 M NaCl, 50 mM EDTA, pH6.5) to 
release the metal ions and remove any remaining viruses or impurities on the column. Flow rate was 
1ml/min. The data represents the average of three independent experiments.  
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Figure 21. Inclusion of 20 mM imidazole in the loading virus suspension and the wash 
buffer resulted in high virus infectivity recovery. 
2 ml KgBHAT crude supernatant (5.3*109 pfu/ml) containing 20 mM imidazole was loaded on an 
IDA-Co2+ column. After loading, the column was eluted with 4ml of 20mM imidazole buffer (PBS-0.5 M 
NaCl, pH6.5), followed by 4ml of pH5.5 buffer (PBS-0.5M NaCl). Finally, the column was passed 
through with an EDTA containing buffer (PBS-0.5 M NaCl, 50 mM EDTA, pH6.5) to release the metal 
ions and remove any remaining viruses or impurities on the column. Flow rate was 1ml/min. The data 
represents the average of three independent experiments.  
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4.2.5 ESR Measurements 
IMAC experiments in the presence of ascorbate suggested that virus inactivation might 
be the result of free radicals generated in the column. To verify this hypothesis, ESR using 
DMPO as a spin trap was employed to directly detect oxygen free radicals.  
As shown in Fig. 22A, a suspension of IDA-Co2+ beads in crude KgBHAT suspension 
generated a 1:2:2:1 quartet with splittings of aN=aH=14.9 G, where aN and aH denote hyperfine 
splittings of the nitroxyl nitrogen and α-hydrogen. Based on these splittings and 1:2:2:1 
lineshape, this spectrum was assigned to DMPO/•OH 165, thus providing direct evidence of  
•OH generation from crude supernatant on IDA-Co2+.  
ESR signal of DMPO/•OH was significantly lower from the IDA-Co2+ beads suspended 
in the partially purified KgBHAT suspension, where most of the soluble impurities were 
removed by centrifugation (Fig. 22B). This explained the relative high infectious virus 
recovery (60%, Fig. 12) when this partially purified suspension was loaded on IDA-Co2+.  
When 20 mM ascorbate was incorporated in the crude supernatant before its mixing 
with IDA-Co2+ beads, ESR detected a doublet with hyperfine splitting aH=1.8 G, a 
characteristic of ascorbate free radical (Fig. 22C) 166. This spectrum indicated that the highly 
reactive •OH was scavenged by ascorbate to give rise to stable ascorbate free radicals. The 
stable ascorbate free radicals do not appear to cause significant KgBHAT inactivation (Fig. 
17).  when the IDA-Co2+ beads were suspended in the same crude supernatant containing 
20mM imidazole, no free radical signal was readily detected (Fig. 22D). This spectrum 
indicated that imidazole prohibited hydroxyl radical generation from Co2+ complexes. The 
absence of detectible hydroxyl free radical in Fig. 22D explained the high infectious virus 
recovery in Fig. 20 and Fig. 21. 
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Figure 22.  Detection of free radicals with ESR. 
DMPO was added to the final concentration of 100 mM in (A) crude KgBHAT supernatant, (B) KgBHAT 
pellet suspension in buffer A, (C) crude supernatant containing 20 mM ascorbate, or (D) crude 
supernatant containing 20 mM imidazole for the use as spin-trap to detect free radicals. Freshly 
prepared IDA-Co2+ beads were mixed with the above samples in room temperature. Five minutes after 
mixing, 10 μl of the bead slurry was transferred into a capillary tube and subjected to ESR 
measurements. 
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4.3 DISCUSSION 
Because dioxygen is a triplet molecule, its reaction with biomolecules is spin forbidden. 
Many transition metals (copper, iron, and cobalt in particular), which exist in several spin 
states, can relieve the spin restriction of dioxygen and enhance the rates of biomolecule 
oxidation 167. There is a large body of literature documenting metal catalyzed oxidation 
(MCO) of biological molecules in solution. However, despite the great popularity of IMAC in 
protein purification, the MCO during an actual IMAC experiment has not been established.  
Considering that IMAC has primarily been used for protein purification, two factors 
may have contributed to the lack of documentation of MCO in IMAC. First, biological 
activity loss may not be discernible for many proteins if the damage does not occur within a 
functional domain. Second, use of any purification step with significant activity loss usually 
will be abandoned and alternative strategies will be explored rather than dedicating 
significant resources for finding the fundamental mechanism of activity loss. In comparison 
to proteins, viruses rely on groups of functional domains from a variety of its surface proteins 
to bind cellular receptors and penetrate into cells during infection. Moreover, the viral 
genome should be free of DNA damage in order to faithfully encode the viral functions. Thus, 
it is likely that viruses are more vulnerable to inactivation than proteins, and could serve as 
better models for studying biological product inactivation during IMAC purification.    
Here we report the inactivation of KgBHAT during the purification on an IDA-Co2+ 
column, particularly when the crude virus supernatant was used as starting material. ESR 
using DMPO as a spin trap detected a strong signal characteristic of DMPO/•OH in the 
inactivating condition. Removal of the soluble impurities by centrifugation significantly 
diminished •OH radical generation, leading to enhanced recovery of virus infectivity. Since  
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the viruses were stable in the crude supernatant, we concluded that the •OH radicals were 
generated from the interaction of the cobalt ions and soluble impurities on the IDA-Co2+ 
column. 
The •OH radicals may have been produced from the uptake and activation of dissolved 
oxygen by chelated Co2+. The ability of Co2+ complexes to bind and reduce dioxygen has 
long been exploited in the applications of dioxygen storage and oxidation catalysis 168-170. 
Upon binding, dioxygen form a mononuclear superoxo or a dinucleat peroxo complex with 
cobalt ion, with a partial electron transfer from the metal center toward dioxygen 168, 170. In 
certain circumstance where there are strong electron-donating ligands and/or solvents, 
irreversible reduction of dioxygen may occur. This reduction could result in the production of 
hydrogen peroxide 168. More importantly, the hydrogen peroxide can react with the chelated 
Co2+ and generate highly reactive hydroxyl free radical through a Fenton reaction: Co2+ + 
H2O2 → Co3+ + •OH + -OH 111, 112, 171. The capability of Co2+ to bind and reduce molecular 
oxygen is highly influenced by the chelating ligands that coordinate with the cobalt 111, 112. 
For example, oxygen binds to a Co2+-(Gly-Gly) complex could result in the oxidation of Co2+ 
to Co3+ and the reduction of oxygen; however, a similar Co2+-(Gly-Gly)-imidazole complex 
is more resistant to irreversible oxidation 172. Furthermore, chelating ligands can modulate the 
oxidation potential of Co2+ to enhance or reduce its capability to generate •OH radicals from 
H2O2 . For example, glutathione (GSH), anserine, and Gly-Gly-His were found to enhance the 
cobalt mediated •OH generation 112. Whereas ADP, citrate, or EDTA can reduce it 111. 
Results present in this study demonstrate that imidazole could reduce the •OH generation on 
the IDA-Co2+, plausibly by diminishing the capability of Co2+ in catalyzing oxygen activation 
and hydroxyl radical generation. On the other hand, the crude virus supernatant contains a 
complex mixture of substances originated from lysed cells during virus replication, which 
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may include hydrogen peroxide, reducing agents, and cellular chelating agents. Upon 
contacting with chelated Co2+ on the IMAC column, these substances may create a favorable 
condition for dioxygen reduction and hydroxyl radical generation.  
The •OH radical could cause protein damage such as fragmentation, carbonyl 
formation, and other single amino acid modification 113. The reaction of •OH radical with 
DNA could result in strand scission, DNA-protein crosslinking, and base modification 116, 173, 
174. Our results (Table. 3) indicated that HSV-1 genome was damaged as the genomes from 
inactivated viruses failed to serve as functional templates for Q-PCR. The direct consequence 
of DNA damage was the loss of viral infectivity.   
The hydroxyl radicals produced on IDA-Co2+ were efficiently scavenged by 20 mM 
ascorbate to generate ascorbate radicals (Fig. 22C). Since the ascorbate radical is much more 
stable than •OH radical 166, virus inactivation is prevented. Although a good free radical 
scavenger in high concentrations, ascorbate could also act as a pro-oxidant capable of 
promoting free radical generation in low concentrations, due to its reducing capability 106. 
The presence of 1 mM ascorbate deteriorated virus inactivation in both crude virus 
supernatant (Fig. 15) and partially purified virus suspension (Fig. 16), with more pronounced 
effect in the later. This more pronounced effect of low concentration of ascorbate in the 
partially purified virus suspension implies that reducing agents from the cell lysate might be 
partially responsible for the catalysis of free radical generation in crude supernatant. 
We also found that imidazole was able to protect KgBHAT from inactivation on 
IDA-Co2+ column. Similar to ascorbate, imidazole has to be present in the loading virus 
suspension during IMAC to impart effective protection. However, it appears that imidazole 
has a different protection mechanism than ascorbate. Rather than acting as a free radical 
scavenger that removes the generated hydroxyl radicals, imidazole prohibits free radical 
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formation in the first place (Fig. 22D), possibly by modifying the catalytic activity of Co2+ in 
oxidative free radical generation. The lack of free radical generation explained the high 
infectious virus recovery when 20 mM imidazole was included in the mobile phase during 
IMAC (Fig20, Fig.21). This result implied that the chelating ligand on IMAC support could 
be carefully designed and optimized so that the chelated transition metal ions will become 
inert or less active in promoting oxidative free radical generation. 
In summary, we demonstrated hydroxyl free radical mediated HSV-1 inactivation on 
immobilized cobalt affinity chromatography where no exogenous hydrogen peroxide or 
reducing agents were intentionally introduced into the column.  Moreover, we demonstrated 
that the inactivation can be reversed by inclusion of appropriate amounts of ascorbate or 
imidazole. The presence of 20 mM ascorbate or imidazole in the mobile phase was highly 
effective in preventing virus inactivation.  The details of the mechanism responsible for free 
radical formation during IMAC may still need further clarification. However, it is of prime 
importance to note that free radical mediated damage might be prevalent in many IMAC 
purifications, particularly in those “one-step purifications” where crude harvest is used as 
starting material. Thus, attention must be given to free radical mediated damage when using 
IMAC for purification of biological products. 
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5.0 CONCLUSIONS 
Recombinant HSV-1 vectors have demonstrated a great potential as delivery vehicles for 
gene therapy applications. As HSV-1 vectors are moving into clinical development, there is 
increasing demand for large quantities of highly purified HSV-1 vectors. Thus, efficient 
production and purification of HSV-1 vectors becomes paramount important. Here, we have 
demonstrated that HSV-1 vectors can be simply and effectively purified using immobilized 
metal affinity chromatography. Outcomes of this study can be summarized as following. 
1. None of the transition metal ions investigated in this study (Cu2+, Ni2+, Zn2+, and 
Co2+) is able to provide a means of separation of untagged HSV-1 virus from protein 
and DNA contaminants. However, of interest is the finding that Co2+ column binds 
negligible amounts of protein, DNA, and virus, suggesting that this column could be 
useful for HSV-1 vector purification if the vector could be endowed with the ability 
to bind to immobilized cobalt.  
2. We constructed an HSV-1 recombinant (KgBHAT) with a cobalt affinity tag (HAT) 
replacing the heparan sulfate binding domain of virion envelope glycoprotein B (gB). 
The productivity of KgBHAT on Vero cells is essentially identical to that of wild 
type HSV-1 (KOS), and the infectivity of KgBHAT is not severely impaired by the 
mutation. 
3. We developed an immobilized cobalt affinity chromatography scheme for the tagged 
HSV-1 virus purification. By correct choice of IMAC parameters such as loading 
condition (pH, ascorbate concentration), flow rate, and chromatographic substrate, 
efficient purification of KgBHAT on immobilized cobalt affinity chromatography 
can be achieved with high virus infectivity yield. 
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4. We found that KgBHAT was inactivated on IDA-Co2+ when crude virus supernatant 
was used as loading material during IMAC (<5% infectivity recovery). Electron 
spinning resonance revealed that the virus inactivation is caused by hydroxyl free 
radicals that are generated from the interaction between cobalt ions and components 
in crude virus supernatant. It has been demonstrated that appropriate amount of 
ascorbate (20 mM), a free radical scavenger, or imidazole (20 mM) in the loading 
material is able to protect HSV-1 virus from inactivation, and leads to high virus 
infectivity recovery after IMAC purification. This finding is the first demonstration 
of oxygen free radical mediated biological inactivation in an actual IMAC 
purification and an effective method to prevent it.  
Using the IMAC parameters optimized in the previous chapters, KgBHAT crude 
supernatant was purified on a 1-ml IDA-Co2+ column, with the results illustrated in Table 5. 
In this demonstration run, a blank IDA column was connected in the downstream of the 
IDA-Co2+ column to minimize metal leakage during purification. 4 ml of KgBHAT crude 
supernatant (2.3*108 pfu/ml) containing 20 mM ascorbate was loaded on the IDA-Co2+. After 
washing with 4 ml of pH6.5 buffer (PBS, 0.5 M NaCl, pH6.5, 20mM ascorbate), the column 
was eluted with 4 ml of pH5.5 buffer (PBS, 0.5 M NaCl, pH5.5, 20mM ascorbate). The 
elution fraction was collected only after passing 2 ml of elution buffer, as little amount of 
recoverable viruses were found to be present in the first 2 ml of elution. As shown in Table 5, 
the final protein concentration in the purified virus stock was 4.4 µg/ml, a reduction of more 
than 97.8 % from the loaded virus stock. The final cellular DNA contaminant concentration 
was 2.9 ng/ml for a reduction of more than 97%. The overall virus infectivity recovery was 
71.1% with about 1.4 fold concentration. In addition, the amount of defective virus particles 
in the purified virus stock was decreased as the ratio of virus genome number to infectious 
virus pfu decreased from 32 to 4.1 during the purification.  
 96
Table 5. Purification of KgBHAT on IDA-Co2+ column 
 
 Before IMAC After IMAC  % Recovery 
2.2 Protein µg/ml 204.4 4.4 
3.0 Cellular DNA ng/ml 96.7 2.9 
Copies of viral genome 7.4*109 1.4*109 18.9 
Virus infectivity pfu/ml 2.3*108 3.3*108 71.1 
Viral genome 
Infectious virus 
32.0 4.1 / 
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